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ABSTRACT 
While cancer is a chronic, complex disease associated with a multitude of steps in its initiation 
and progression, all cancers generally have similar underlying maladaptive physiological 
mechanisms which may be addressed in order to prevent or treat this disease. Interest in the 
context of this thesis was in two of these maladaptive mechanisms, namely inflammation and 
oxidative stress. Both unresolved or severe inflammation and oxidative stress have been 
associated with cancer aetiology, and therefore administration of an anti-inflammatory or 
antioxidant could potentially prevent the initiation and progression of cancer. Current 
conventional cancer therapies are associated with a wide range of adverse side effects, 
leading to much interest in plant-based alternatives. For the purpose of this thesis, Δ-7 
mesembrenone, a potent antioxidant isolated from Sceletium tortuosum and Cannabidiol, an 
antioxidant and anti-inflammatory extracted from Cannabis sativa, were studied in the 
context of breast cancer treatment.  
The potential anti-cancer activity of Δ-7 mesembrenone and Cannabidiol were investigated in 
three breast cell models in vitro. MCF12A, MCF7 and MDA-MB-231 cells were treated with 
varying doses of Δ-7 mesembrenone and Cannabidiol in isolation or in combination for a 
period of 24 hours, and the effects on cell viability and mitochondrial reductive capacity were 
assessed. Following this, the ROS production and the GSH/GSSG ratio were determined. 
Δ-7 mesembrenone in isolation resulted in cytotoxicity and increased ROS production across 
all cell models. Cannabidiol exposure in estrogen receptor positive breast cancer resulted in 
reductions in cell viability and mitochondrial reductive capacity, corresponding to an 
increased ROS production in these cells. No toxic effects of CBD were evident in the estrogen 
receptor negative breast cancer or normal breast cells at lower doses. Finally, combination 
treatments resulted in adverse effects across all cell models and at combined high doses, the 
negative effects were cumulative. 
We conclude that Δ-7 mesembrenone has no benefit in the context of breast cancer, as it 
exhibited significant levels of cytotoxicity in normal healthy breast cells at all concentrations 
reducing cancer cell survival, which could not be countered by Cannabidiol co-treatment. 
Cannabidiol showed more promise as an anti-cancer drug due to its high levels of cytotoxicity 
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and the increased ROS production it induced in the estrogen receptor positive breast cancer 
cell line. Both the normal breast cells and the estrogen receptor negative cells exhibited little 
side effects than can be ascribed to Cannabidiol, illustrating the importance of this treatment 
in certain types of breast cancer only. Further research is warranted to better elucidate the 
cellular mechanisms involved and potential for treatment with this extract.  
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UITREKSEL 
Hoewel kanker ‘n chroniese en komplekse toestand is wat gepaardgaan met verskeie stappe 
in terme van oorsprong en progressive, het all kankers ooreenstemmende onderliggende 
wanaanpassings van fisiologiese sisteme wat geaddresseer kan word om die siekte te 
behandel of te voorkom. In die konteks van hierdie tesis is twee van hierdie wanaangepaste 
meganismes, inflammasie en oksidatiewe stres, van spesifieke belang. Beide hierdie 
meganismes word geassosieer met kanker etiologie. Dus kan toediening van anti-
inflammatoriese or anti-oksidant middels potensieel teen kanker beskerm. Huidige 
konvensionele kankerterapie word gekenmerk deur ‘n verskeidenheid newe-effekte, wat 
gelei het na belangstelling in plantverwante alternatiewe. Vir die doel van hierdie tesis, is Δ-
7 mesembrenoon, ‘n sterk anti-oksidant geïsoleer uit  Sceletium tortuosum,  en kannabidiool, 
‘n anti-oksidant en anti-inflammatoriese middel uit  Cannabis sativa, in die konteks van 
borskanker bestudeer.   
Die moontlike teenkanker aktiwiteit van Δ-7 mesembrenoon en kannabidiool is in vitro in drie 
borskanker selmodelle ondersoek. MCF12A, MCF7 en MDA-MB-231 selle is met ‘n 
verskeidenheid dosisse van Δ-7 mesembrenoon en kannabidiool, in isolasie of in kombinasie, 
behandel vir 24 uur, gevolg deur ‘n assessering van die effekte op sel lewensvatbaarheid en 
mitokondriale reduktiewe kapasiteit . Hierna is reaktiewe suurstof spesie (RSS) produksie en 
die GSH/GSSG verhouding bepaal. 
Δ-7 mesembrenoon op sy eie was sitotoksies en het verhoogde RSS produksie in alle seltipes 
tot gevolg gehad. Kannabidiool blootstelling in estrogeen reseptor positiewe borskankerselle 
het verlaagde seloorlewing en mitokondriale reduktiewe kapasiteit veroorsaak, wat 
ooreenstem met die verhoogde RSS produksie in hierdie sellyn.  Geen toksiese effekte van 
kannabidiool was sigbaar in estrogeen negatiewe selle by laer dosisse nie. Laastens het die 
kombinasie behandeling newe-effekte gehad in alle modelle – hierdie effekte was kumulatief 
by hoër dosisse. 
Ons gevolgtrekking is dat Δ-7 mesembrenoon geen voordeel in die konteks van borskanker 
inhou nie, aangesien dit toksies was vir normale selle by alle konsentrasies wat kankersel 
oorlewing beperk het. Hierdie negatiewe effek kon nie voorkom word deur byvoeging van 
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kannabidiool nie. Kannabidiool het meer belofte ingehou as teenkankermiddel deur 
verhoogde sitotoksisiteit en RSS produksie wat dit in estrogeen reseptor positiewe selle tot 
gevolg gehad het. Beide normale en estrogeen negatiewe selle het min newe-effekte op 
kannabidiool gewys, wat die potensiaal van kannabidiool behandeling in sekere kankertipes 
uitwys.  Verdere navorsing sal help om die meganismes betrokke op sellulêre vlak, verder te 
belig.   
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CHAPTER ONE: INTRODUCTION 
 
Cancer is a chronic disease responsible for more than 20% of the deaths occurring each year 
worldwide. This already massive disease burden is only anticipated to become more severe, 
with millions of new cases predicted annually. Breast cancer specifically is the most frequently 
diagnosed cancer in women, and upwards of 500 000 deaths each year are as a result of 
breast cancer. 
Cancer in general is a highly complex disease, characterised by a multistep process resulting 
in tumorigenesis, progression and invasion. While varying types of cancer all have their own 
disease specific triggers, all cancers have the same maladaptive physiological mechanisms and 
processes, and once these may be addressed, tumour initiation and progression may be 
limited or inhibited entirely. Of particular interest in the context of this study was 
inflammation and oxidative stress, both implicated directly in the development and 
progression of carcinogenesis. 
Both inflammation and oxidative stress are important biological processes necessary for 
survival and are beneficial to the host at a certain threshold. Acute inflammation which is 
resolved quickly is a key component of innate immunity, tissue repair and detoxification, 
while oxidative stress is an important mediator of signalling and host defence. However, when 
inflammation and oxidative stress remain unresolved, potential cellular targets may become 
oxidised and degraded resulting in detrimental effects, one of which is carcinogenesis. 
Therefore, in order to prevent or treat carcinogenesis, antioxidant and anti-inflammatory 
agents may prove very beneficial. 
Current traditional cancer treatments such as chemotherapy and radiation have been 
associated with many adverse side effects, high expenses and secondary toxicity in response 
to anti-cancer drugs. For this reason, a large body of current research has shifted its focus to 
plant-based therapies for as potential anti-cancer agents. Plant-based medication is 
associated with far fewer adverse side effects and has shown potential in treatment of other 
inflammatory and oxidative stress-based diseases, such as neurodegeneration, arthritis and 
inflammatory bowel disease. 
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For the purpose of this thesis, two plant-based compounds were studied, namely Δ-7 
mesembrenone isolated from Sceletium tortuosum and Cannabidiol isolated from Cannabis 
sativa. Δ-7 mesembrenone has recently been determined to be a powerful antioxidant, and 
Cannabidiol has both anti-inflammatory and antioxidant properties. These compounds were 
studied in the context of treatment of breast cancer, and the resolution of the oxidative 
stress associated with this disease.  
Aims of this study included determination of the effect of exposure with two plant-based 
extracts, Δ-7 mesembrenone isolated from Sceletium tortuosum and Cannabidiol isolated 
from Cannabis sativa, in isolation and in combination, on normal breast (MCF12A) and breast 
cancer (MCF7 and MDA-MB-231) cell viability. In addition to this, the study aimed to elucidate 
the relevant cellular mechanisms involved related to redox status by which the extracts exert 
their effects on cell survival. Finally, we aimed to assess potential interaction effects of the 
two plant extracts in this context. 
This thesis begins with a review of all the relevant literature studied in order to better 
understand the mechanisms involved in oxidative stress, inflammation and their role in 
carcinogenesis, as well as the potential of phytomedicines in this context. Following this, the 
methods and the materials used for this study are described, after which the results obtained 
are displayed. This thesis then ends off with a discussion of the results attained, and the 
relevant conclusions drawn from this study. 
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CHAPTER TWO: LITERATURE REVIEW 
 
2.1 Introduction 
Chronic disease, and more specifically the chronic non-communicable diseases, typically have 
a relatively long maladaptive progression before clinical onset, and are the result of 
physiological, environmental, genetic and behavioural factors (World Health Organisation, 
2018). The 4 main non-communicable diseases are cardiovascular disease, cancer, chronic 
respiratory diseases and diabetes, and risk factors for these diseases include lack of physical 
activity, unhealthy diets, tobacco use and harmful alcohol consumption. People globally from 
all countries and regions, both developing and developed, are affected by non-communicable 
diseases, however a higher prevalence is observed in developing countries. According to the 
World Health Organisation (WHO), these diseases are responsible for 71% of the deaths 
worldwide annually, with 42% of these deaths being the result of cardiovascular disease and 
22% due to cancer (World Health Organisation, 2018).   
Within South Africa specifically, a significant health transition is occurring, with an 
approximate 400% increase in the incidence of chronic disease in both rural and urban areas 
within the last 20 years. This growing burden has placed an ever-growing pressure on both 
short and long-term healthcare services nationwide (Mayosi et al., 2009). While a massive 
increase in non-communicable disease burden has already been experienced, this burden is 
only expected to become more severe, partially due to the emergence of anti-retroviral 
medication (ARVs).  This treatment has resulted in higher mortality and prolonged death in 
HIV/AIDS infected patients, with more than 3.4 million people in South Africa alone using ARV 
treatments, making it the largest ARV treatment programme in the world (Moyo et al., 2018). 
Expansion in these health programs have resulted in a decrease in the amount of deaths in 
South Africa that are due to communicable disease, such as HIV and tuberculosis. This in part 
has resulted in an increase in the age of the population, which lends itself to an increase in 
the incidence of chronic disease, such as cancer and cardiovascular disease. Focus now has 
shifted to combat these non-communicable diseases (Statistics South Africa, 2017). For the 
purpose of this thesis, I will focus on cancer, and in particular, breast cancer. 
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2.2 Cancer 
2.2.1 Epidemiology 
Cancer is the second leading cause of death worldwide, and thus poses a large burden 
economically on developing and developed countries alike (Torre et al., 2015). This burden of 
cancer is increasing every year, and the WHO predicts 20 million new cancer cases annually 
from as early as 2025, with continuation of this escalation over the following decades (World 
Health Organisation, 2011). Developing countries are typically characterised by late diagnosis 
and limited treatment access, resulting in more deaths from chronic disease (Torre et al., 
2015). Factors such as increased population age, as well as cancer-promoting lifestyle choices 
also contribute to the poor prognosis of cancer (World Health Organisation, 2008). 
Breast cancer is the most frequently diagnosed cancer in women worldwide, as well as the 
leading cause of cancer deaths in females. In 2012 alone, there were 1.7 million cases of 
breast cancer, and 521900 deaths caused by this disease around the world (Torre et al., 2012). 
Year after year, more and more health data are collected globally which demonstrate the 
ever-increasing mortality, incidence and economic burden of breast cancer, and this is only 
predicted to increase annually (Coughlin et al., 2009).  
 
2.2.2 Breast cancer risk factors 
There are multiple risk factors associated with developing breast cancer. Such risk factors 
include firstly, age, whereby the risk is doubled in women every 10 years up until menopause 
is reached, after which the risk dissipates dramatically (Willett et al., 2000). Secondly, the age 
at which women begin mensuration and the age at which menopause starts also plays a role. 
Studies have shown that women who menstruate early in life, or women who develop 
menopause after the age of 55 are at a higher risk of developing the disease (McPherson, et 
al., 2000). Thirdly, family history also plays a vital role, and up to 10% of breast cancer cases 
are related to a genetic predisposition and are generally inherited through genes such as 
BRCA1 or BRCA2 (DeMichele and Weber, 2000). However, in the context of this these, the 
role of estrogen in the development of breast cancer and the resulting oxidative stress is of 
particular interest. 
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Sex hormones are implicated in the carcinogenesis of many different types of human cancers, 
and there is a plethora of experimental data across multiple studies obtained over decades 
which indicates that estrogen plays a critical role in the development and progression of 
breast cancer (van Leeuwen et al., 2000). Increasing evidence suggests that an increase in 
estrogen exposure is associated with a greater risk of developing breast cancer, and estrogens 
may act as carcinogens through mechanisms involving oxidative stress in the kidney, liver and 
breast tissues of various rodent models (Harvel et al., 2000). In comparison to the oxidative 
stress levels seen in normal breast tissue, cancerous breast tissue has a much higher amount 
of oxidative DNA damage, and this has a strong correlation with the estrogen receptor status 
of the breast tissue studied (Mussarat et al., 1996). Estrogen receptors are responsible for 
retaining estrogen intracellularly and have a very high affinity for estrogen binding (Kuiper et 
al., 1997). There is evidence to suggest that breast cancer cells which are estrogen receptor 
positive (ER+) have a greater sensitivity to oxidative stress levels, as they do not metabolise 
the reactive oxygen species as efficiently as estrogen receptor negative (ER-) breast cancers 
(Mobley and Brueggemeier, 2004). Furthermore, the presence of estradiol (E2), one of the 
primary estrogens in women, has been linked to increased sensitivity of breast cancer cells to 
oxidative damage (Liehr, 1999). 
 
2.2.3 Cancer aetiology 
Extensive cancer research has generated a large body of knowledge about the disease in 
general, and how tumorigenesis is characterised by multistep processes resulting in genetic 
mutations, which are the driving force behind the change from normal, healthy cells to highly 
malignant derivatives of the host (Hanahan and Weinberg, 2000). Most notably, there are 
mutations in the genome resulting in an acquisition of function of oncogenes, while a loss of 
function is seen in tumour suppressor genes, resulting in the promotion of cancer progression 
(Bishop and Weinberg, 1996).  
 Multiple theories exist in which the causation and origin of cancer are described, most 
notably and commonly described of which is Hanahan and Weinbergs “Hallmarks of Cancer”. 
This theory describes certain biological capabilities that are acquired during the process of 
tumour development, allowing initiation of the tumour development as well as metastasis of 
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the cancer. These hallmarks are self-sufficiency of growth signals, insensitivity of anti-growth 
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, invasion 
and metastasis, deregulated metabolism, genome instability, immune system evasion and 
inflammation (Hanahan and Weinberg, 2011). This theory demonstrates that while all types 
of cancer have their own unique aetiology, all cancers share similar maladaptive physiological 
mechanisms and processes. If these maladaptation’s may be addressed, tumour initiation and 
cancer progression could potentially be limited or removed entirely. 
For this study, one of the most interesting hallmarks is that of inflammation, due in part to 
the fact that it is crucial, as inflammation is implicated directly in the perpetuation of many of 
the other hallmarks of cancer (Hanahan and Weinberg, 2011). Interlinked with the hallmark 
of inflammation is that of oxidative stress, as oxidative stress results from the inflammation 
occurring during cancer, and may also contribute to tumour initiation and progression. 
Therefore, in the following section I will be reviewing these two important processes that are 
interlinked in the context of cancer. While these are two general cancer-related processes I 
will be focussing on, it is important to note that all types of cancer have their own unique 
range of disease-specific triggers and factors that culminate to result in their own 
carcinogenesis and tumour progression pathways. However, this falls outside of the scope of 
this thesis, and for the purpose of my study I will be focussing specifically on oxidative stress 
and how it is related to inflammation.  
 
2.3 Common exacerbating role players in cancer  
2.3.1 Oxidative stress 
Increased oxidative stress is associated with the pathogenic mechanisms of many diseases, 
including non-communicable diseases such as cancer and diabetes mellitus; inflammatory 
diseases; neurodegenerative diseases such as Parkinson’s and Alzheimer’s; as well as the 
process of ageing (Durackova, 2010). Interestingly, cumulative oxidative damage and repair 
cycles – which is the basis for physiological ageing – seems to be upregulated in all non-
communicable diseases and seems to result from “accelerated ageing” (Petersen and Smith, 
2016). This common aetiology suggests that an understanding of the process of oxidative 
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stress, as well as knowledge on how to limit or counter it, may be applicable more widely than 
to cancer alone. 
Oxidative stress may be defined as the imbalance between the production of free radicals, 
namely reactive oxygen species (ROS), and their removal via antioxidant systems, functioning 
to protect important biomolecules and organs from potential damage resulting from this 
imbalance (Reuter et al., 2010). Therefore, stress begins to occur when the net influx of ROS 
is greater than the particular cells ability to detoxify the detrimental reactive species (Wellen 
and Thompson, 2010). The term reactive oxygen species (ROS) includes among others, the 
superoxide anion (O2-), hydroxyl radical (OH●), hydrogen peroxide (H2O2), peroxynitrite 
(ONO2-) and nitric oxide (NO) (Ingram and Diotallevi, 2017). Formation of free radicals 
generally starts with O2 and results in the formation of reactive species such as H2O2 and OH● 
as seen in the reactions illustrated in Figure 2.1. 
 
 
 Figure 2.1 – Types of Reactive Oxygen Species (ROS) (Rodriguez and Redman, 2005) 
 
2.3.1.1 Sources of free radicals 
Free radicals may either come from endogenous sources, such as the mitochondria, 
peroxisomes and the endoplasmic reticulum, or they can originate from exogenous sources 
such as tobacco smoke, pesticides and alcohol. While these free radicals have many important 
biological functions, an alteration in the balance of these reactive species may result in 
increased oxidative stress.  
One of the primary sources of endogenous free radical production are the mitochondria. 
Oxidative phosphorylation is the main source of energy production in eukaryotic cells, and it 
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occurs via the reduction of O2 at the mitochondria to H2O (Sorbara and Girardin, 2011).  The 
reduction of O2 generates an H+ gradient which drives the synthesis of ATP, and this process 
results in the formation of many intermediate products, such as H2O2.  This occurs during the 
electron transport chain, whereby the membrane-impermeable superoxide anion (O2-) is 
generated within the inner membrane of the mitochondria. This anion is then converted to 
H2O2 via mitochondrial dismutase, and then moves into the cytoplasm out of the 
mitochondria.  
While the mitochondria are a rich source of ROS formation, peroxisomes are also main 
producers of free radicals. Peroxisomes are small organelles which have a vital role in lipid 
metabolic pathways, such as fatty acid α- and β-oxidation and ether-phospholipid 
biosynthesis. Peroxisomes contain certain enzymes, such as urate oxidase and polyamine 
oxidase, that are responsible for the production of H2O2, which forms a part of their normal 
catalytic cycle (Antonenkov et al., 2010). These organelles also contain xanthine oxidase and 
nitric oxide synthase, which result in the production of O2- and H2O2, and NO respectively. 
Finally, another rich source of free radical generation is the NOX family of NADPH oxidases. 
These are enzymes involved in the transport of electrons across plasma membranes, as well 
as the production of the superoxide anion and other ROS. Therefore, NADPH oxidases serve 
almost exclusively as ROS-generating enzymes. NADPH oxidases are found in many areas 
throughout the body, such as in phagocytes, fibroblasts, tumour cells and vascular smooth 
muscle (Szatrowski and Nathan, 1991).  
 
2.3.1.2 Oxidative damage in cells 
Production of free radicals is necessary and beneficial for the survival and functioning of the 
organism for several reasons. Firstly, ROS are key players in host defence, and they are 
involved in the digestion of invading pathogens and debris (Oliveira et al., 2010). Secondly, 
they function as signalling molecules through reversibly oxidising protein thiol groups, and 
are involved in processes such as signal transduction, disulphide bond formation, gene 
expression and control of the caspase activity which is activated during apoptotic mechanisms 
(Sosa et al., 2013). These growth and repair mechanisms are achieved through use of the 
mitochondrial electron transport chain, as well as through use of several enzymes within the 
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host, namely cytochrome P450, xanthine oxidase, the NADPH-oxidase enzyme complex, 
amongst several others. Studies have also revealed that endoplasmic reticulum-generated 
ROS have important functions in protein folding (Santos, et al., 2009).  
While ROS are very important for certain fundamental cellular events, their reactivity may be 
harmful if the wrong targets are oxidised. Potential targets leading to undesired outcome 
include macromolecules, such as DNA, lipids and proteins. Free radicals can oxidise 
polyunsaturated fatty acids in lipids, and initiate lipid peroxidation, which can ultimately 
result in loss of fluidity in the membrane and thus disrupt membrane proteins (Cabiscol et al., 
2000). DNA is also a major target for free radicals in which both the base and the sugar 
molecules may be oxidised, as seen in figure 2.2, resulting in double and single stranded 
breaks in the backbone and within the base and sugar groups, and crosslinks may be formed 
with other molecules, thereby blocking replication of certain genes (Sies, 1992). This type of 
damage to DNA is associated with mutagenesis and carcinogenesis (Breen and Murphy, 
1995). 
 
 
Figure 2.2. – Harmful reaction of the hydroxyl free radical with the sugar moiety of DNA (Nimse and Pal, 
2015) 
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2.3.1.3 ROS generation in cancer cells vs normal cells  
Increased oxidative stress and ROS have been associated with cancer for a long period of time, 
in both the initiation and progression of cancer, the phenotypic behaviour of cancer cells, as 
well as the response to treatment interventions (Sabharwal and Schumacker, 2014). This 
association can be highly complex, and sometimes even paradoxical.  
Firstly, it has been observed that there is a relationship between ROS and the genesis of 
cancer (Schumacker, 2015). Within what is known as the “mitochondrial paradigm” in cancer, 
it has been demonstrated that mutations within either nuclear or mitochondrial DNA 
associated with the electron transport chain, potentially caused by hypoxia, can result in an 
increase in the production of reactive species (Wallace, 2005). This then results in a build-up 
of electrons within the chain, which can then be used to form superoxide, which can be 
converted into H2O2 by superoxide dismutase (Schumacker, 2006). This H2O2 is then free to 
leave the mitochondria, whereby it can oxidise potentially harmful targets, such as certain 
macromolecules, like DNA, introducing genetic instability. Over time, as the mitochondrial 
ROS production increases, there is an increase in Hypoxia Inducible Factor 2α (HIF-2α), a 
transcription factor which suppresses DNA mismatch/repair processes, further perpetuating 
and accumulating the malignant DNA mutations, driving the transformation of the cell to 
becoming malignant (Ralph et al., 2010). Another Hypoxia inducible factor, HIF-1, has also 
been linked to cell survival in the presence of increased ROS, as its activation by reactive 
species enhanced the survival and development of tumours through gene upregulation 
involving glycolysis, angiogenesis and other cell metabolic pathways (Gao et al., 2007). 
Secondly, there is evidence to suggest that certain cancer types are characterised by an 
increase in ROS production, in comparison to that of a normal, non-cancerous cell type. This 
is predicted to be as a result of the constitutive activation of cell proliferation pathways 
(Trachootham et al., 2006). Cell proliferation in normal cells is as a result of growth factor 
stimulation, and this requires ROS for cell signalling. Therefore, it stands to reason that in 
cancer cells, characterised by an increased proliferative rate, there would be increased ROS 
present for cell signalling to occur. However, there has been some speculation that this 
increased ROS production could actually be due to a higher metabolic rate, rather than an 
oncogenic transformation (Ferreira, L.M., 2010). More research is required to fully elucidate 
this. 
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Although the pathways described above drive the malignancy towards proliferation and 
survival, they do eventually generate a level of oxidative stress that becomes too severe for 
the cancer cells to cope with. This introduces the third difference between cancerous and 
non-cancerous cells, whereby there is a greater expression of the endogenous antioxidant 
thioredoxin reductase within cancerous cell types (Schumacker, 2006). The thioredoxin 
system, made up of NADPH, thioredoxin reductase and thioredoxin, is one of the systems 
involved in the proliferation, viability and apoptosis of cancer cells (Lu et al., 2007). This 
system is upregulated through a shift in the tumorigenic cells glycolytic pathway, where it is 
reprogrammed to increase flux through the pentose phosphate pathway to ensure an 
adequate supply of NADPH, one of the main driving forces of the cells antioxidant capacity 
(Sabwharal and Schumacker, 2014). Following this, thioredoxin reductase is expressed in 
response to elevated concentrations of free radicals, and it is translocated to the nucleus to 
ensure maintenance of a reducing environment. This allows for binding of transcription 
factors with DNA, allowing gene expression to continue even when oxidative stress levels are 
increased (Holmgren, 2008). This endogenous antioxidant is typically over expressed in 
malignant cells, further driving them towards tumour progression via cell proliferation, 
despite increased levels of oxidative stress.  
Although these mechanisms manipulate the endogenous ROS levels to ensure tumour cell 
survival and progression, cancerous cells can be killed by agents which increase ROS levels 
even further, beyond the point of survival of the malignancy, which is the usual strategy for 
current traditional therapy. This can either be achieved through addition of a chemical agent 
which would increase ROS production, such as histone deacetylase inhibitors, or by 
decreasing the capability of the cell to scavenge free radicals, such as β-phenylethyl 
isothiocyanate (Adachi et al., 2004). This appears to be selectively toxic to tumour cells, as 
they have an already increased level of ROS production, essential for their rate of growth and 
signalling, whereas normal cells have a much lower oxidant stress baseline, and therefore 
addition of these compounds resulted in a less severe change in oxidant signalling levels 
(Schumacker, 2015). This illustrates the delicate nature of the redox status of the cell in 
question, and how changes in oxidative stress or ROS levels may potentially make the 
difference between a cellular microenvironment that is tumour promoting or one which is 
tumour suppressing, as illustrated in figure 2.3. 
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Figure 2.3 – The relationship between cellular oxidative stress and tumorigenesis/tumour suppression. (Galadari 
et al., 2017).  
 
2.3.1.4 Endogenous antioxidant systems 
Most cells or host organisms possess intercellular mechanisms to evade or diminish the threat 
and damage caused by these free radicals, namely antioxidants. Antioxidants are substances, 
enzymatic and non-enzymatic, which when present at low concentrations in comparison to 
the oxidative species substrate, may significantly delay or prevent oxidation of that substrate 
(Sies, 1997). Enzymatic antioxidants found within the hosts natural defence mechanism 
includes glutathione peroxidase, superoxide dismutase (SOD), glutathione and several others. 
Antioxidants can also be obtained through dietary intake, either through daily supplements 
or via eating healthy foods such as fruits and vegetables. The fine balance between 
antioxidants and free radicals illustrates the importance of these antioxidants, and if the 
balance is shifted towards a molecular environment with higher concentrations of ROS, 
targets necessary for maintaining homeostasis start to become oxidised, creating potential 
downstream adverse effects. 
Antioxidants may be enzymatic or non-enzymatic and both modulate the free radical 
reactions. Typically, enzymatic antioxidants react with free radicals and either break them 
down or leave them non-reactive, and most often are functioning to reduce the levels of lipid 
hydroperoxide and H2O2. Thus, they are vital for maintaining the integrity of cellular 
membranes and prevention of lipid peroxidation. The main enzymatic antioxidants are 
catalase (CAT), Glutathione peroxidase (GSHPx), Superoxide Dismutase (SOD) and 
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Peroxiredoxin (Prx) (Nimse and Pal, 2015). SODs are typically located in the cytosol and 
mitochondria and are responsible for the conversation of the superoxide anion into oxygen 
and H2O2 using a metal cofactor (Copper, Zinc etc.). CAT is found in peroxisomes and is 
responsible for the formation of water and oxygen from H2O2 (Zhan et al., 2004). GSHPx and 
Prx are located primarily in the cytosol and are used to convert H2O2 into water (Cabsicol el 
al., 2000). Below is a table summarising these reactions mentioned.  
 
 
Figure 2.4 – The main enzymatic antioxidants, their cellular locations and the reactions they catalyse 
(Nimse and Pal, 2015). 
 
Non-enzymatic antioxidants are most often what are known as chain-breaker antioxidants, as 
they are involved in halting the cascade for the formation of free radicals (Bolann and Ulvik, 
1997). Examples of non-enzymatic antioxidants are vitamin E, vitamin C and vitamin A 
(Tafazoli et al., 2005), bioflavonoids such as flavone and flavanol (Pietta, 2000) and 
carotenoids such as β-carotene (Olsen and Krinsky, 1995). These chain-breaking antioxidants 
are typically involved with preventing the propagation and elongation steps in the formation 
of free radicals from lipids, and thus prevent the generation of these free radicals.  
It is important to note that beneficial antioxidant capacity of antioxidants may be lost if the 
antioxidant in question is administered at a dose which is too high. This may result in the loss 
of their radical-scavenging function, and may shift the antioxidant behaviour towards a pro-
oxidant, which exacerbates the problem of oxidative stress and may result in further cellular 
damage occurring (Burkitt, 2001). Therefore, antioxidants should be administered with 
caution, and at doses which are safe in order to achieve the desired free radical scavenging 
effects. 
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There is evidence to suggest that treatment with antioxidants can serve a protective role as 
preventative agents against cancer development and tumour initiation, as well as serve as 
effective treatment in combating tumour growth and progression (Block et al., 2008).  
 
2.3.1.5 Assessing redox status 
There are many in vitro and in vivo methods for assessing the redox status of a cell/organism, 
but for the purpose of this study I will be focussing on assessing the H2O2 reactive species 
production in vitro as well as the antioxidant capacity of an endogenous antioxidant, namely 
glutathione, in vitro.  
In order to elucidate the level of oxidative stress within cells, one can determine the amount 
of H2O2 present within the cell. This is a convenient way, as H2O2 has the longest half-life of 
all ROS species produced within a cell, and various other reactive species are converted into 
H2O2 (Newsholme et al., 2012). An example of this would be the conversion of the superoxide 
anion to H2O2 and water via SOD. Therefore, a change in the H2O2 levels within the cell could 
be indicative of changes in the oxidative stress levels being experienced within the cells. A 
potential assay that could be used to detect the levels of H2O2 within cells is the ROS-GloTM 
H2O2 Assay from Promega (Promega, USA).  
Another effective way of determining the redox status of a cell is to determine the 
endogenous antioxidant capacity of that cell. This could then give insight as to the 
susceptibility of that certain cell type to increases in oxidative stress levels, and the capacity 
of the cell type to deal with different levels of oxidative stress. An example of this would be 
using the GSH/GSSG-GloTM Assay from Promega (Promega, USA). This assay allows one to 
determine the ratio between reduced Glutathione (GSH) and oxidised Glutathione (GSSG) 
within a cell following exposure to increased levels of oxidative stress. Glutathione is an 
abundant antioxidant present in eukaryotic cells, most of which exists as GSH. Certain 
chemicals react with GSH to form GSSG, decreasing the ratio of GSH/GSSG present in the cell. 
Changes in the ratio of GSH/GSSG is associated with a diseased state of the cell, and indicates 
higher levels of oxidative stress. 
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2.3.2 Inflammation 
Just as oxidative stress plays a key role in normal healthy functioning and host survival, 
inflammation is a vital process involved in normal body functioning. Sources of inflammation 
are widespread, and include bacterial or viral infections, exposure to allergens, radiation or 
toxic chemicals, autoimmune and chronic diseases, obesity, consumption of alcohol, tobacco 
use, and a high calorie diet (Aggarwal et al., 2009; Scetter et al., 2010). Inflammation is largely 
non-specific, but it interacts with many other innate and adaptive immune processes to 
strengthen the body’s resistance to pathogens and mutated cells. 
The initial stage of inflammation, known as acute inflammation, is mediated through 
activation of the immune system. This inflammation is resolved after a short period of time 
and has shown many benefits within the host organism (Reuter, et al., 2010). Some of these 
benefits include detoxification, facilitation of the healing process, tissue repair and removal 
of infection. If inflammation persists for a longer period, it is classified as chronic 
inflammation, and this can be detrimental to the host and may result in development of a 
wide array of chronic diseases, including cancer. The longer the inflammation persists, the 
higher the risk of cancer (Reuter et al., 2010).  The process of inflammation is a complex, 
multifaceted process. However, a comprehensive review on inflammation is beyond the 
scope of this thesis. Therefore, rather, the next section will focus specifically on how 
inflammation may exacerbate cancer progression, and more specifically how it links to 
oxidative stress in this context. 
 
2.3.2.1 Inflammation in cancer 
Despite the fact that inflammation serves as a localised protection for tissue irritation or 
infection and thereby is vital for optimum function and protection of the host organism, it 
also has a negative impact in many chronic diseases such as cancer, diabetes, etc. Chronic 
inflammation is one of the hallmarks of many different types of cancers, and it has been 
observed that chronic inflammation over long periods of time results in a 15-20% higher risk 
of developing cancer in our lifetime (Del Prete et al., 2011). Unresolved inflammation due to 
any failure in the immune response may disrupt the cellular microenvironment, which could 
result in genetic mutations in cancer-related genes, DNA repair mechanisms, and 
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posttranslational modifications in proteins involved in the cell cycle. Furthermore, 
inflammatory cells themselves may also contribute to tumour progression within the tumour 
microenvironment, as well as to angiogenesis and metastasis (Eiro and Vizoso, 2012).  
In terms of cancer initiation and inflammation, one of the first links is the presence of 
macrophages at the site of tumour initiation and development and may be found in areas 
demonstrating hyperplasia, a very early stage in cancer initiation (Mantovani et al., 2006). 
Macrophages are an essential part of the hosts immunity, and in the context of regular 
inflammation and day to day normal functioning, they play a very crucial role in immune 
regulation, wound healing, removal of invading microbes, etc. However, in the context of 
cancer, macrophages can contribute to the process of carcinogenesis. Macrophages are 
associated with promoting tumour growth through creation of an inflammatory environment 
which is mutagenic via the generation of reactive oxygen species, an example of the link which 
exists between oxidative stress and inflammation (Qian and Pollard, 2010). This mutagenic 
environment may result in activation of certain oncogenes or cancer supressing genes, as well 
as certain transcription factors involved in tumour initiation and progression. 
In addition to macrophages, neutrophils and mast cells can also drive the process of 
tumorigenesis. Neutrophils are an essential player in the innate immune response and are 
often the first responders to sites of infection and function to remove invading microbes or 
pathogens, and thus are extremely important in the inflammatory response. Mast cells also 
play an important role in host defence and are activated during the inflammatory response 
to secrete mediators, cytokines and histamine, all necessary to remove invading pathogens 
and infection. However, in the context of cancer, both neutrophils and mast cells may 
upregulate the production of non-specific pro-inflammatory cytokines such as tumour 
necrosis factor (TNF), interleukin-1α (IL-1α) or IL-1β, or IL-6, present during an immune or 
inflammatory response, and this contributes to carcinogenesis (Aggarwal et al., 2006). 
Although TNF contributes to carcinogenesis (Wang and Lin, 2008), this factor also has an 
important role in inflammation, and is involved in cell survival, cell proliferation and cell 
death. However, in terms of carcinogenesis, TNF exerts its cancer effects through signalling 
the transcription factor nuclear factor-κβ (NF- κβ) (Feller et al., 2013). This has been observed 
to be one of the primary links between inflammation and tumour initiation and has been 
observed to allow preneoplastic as well as malignant cells to evade apoptosis (Karin and 
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Naugler, 2008). NF- κβ has also been implicated in the expression of several pro-inflammatory 
gene products, such as IL-1β, IL-1α, IL-8, chemokines, Cyclooxygenase-2 (COX-2), etc., all of 
which play a critical role in suppressing apoptosis, promoting angiogenesis, metastasis and 
invasion (Avalle, et al., 2017). It is therefore no surprise that NF- κβ has been found to be 
constitutively active in most tumours, and again illustrates the link between inflammation and 
cancer. 
Following tumour development, a different mechanism of inflammation can ensue which may 
allow for the survival of the tumour in the host. Most malignancies trigger an inflammatory 
response, creating a tumour-promoting microenvironment (Mantovani, et al., 2008). 
Oncogenes, such as the RAS gene, when expressed can result in the recruitment of leukocytes 
and tumour-promoting chemokines, further perpetuating the malignancy. In addition to this, 
an “angiogenic” switch may be activated, allowing angiogenesis to occur (Soucek et al., 2007). 
Following growth of the tumour, the malignancy eventually becomes nutrient deprived and 
experience hypoxia due to a limited blood supply. This causes necrosis to occur at the core of 
the tumour, which results in the expression of pro-inflammatory cytokines, such as IL-1 and 
vascular endothelial growth factor (VEGF) (Vakkila and Lotze, 2004). This inflammatory 
response then triggers angiogenesis, allowing the remaining cancer cells to be provided with 
the nutrients and growth signals necessary for their survival (Grivennikov et al., 2010). 
While many epidemiological studies have shown that chronic inflammation predisposes 
individuals to certain cancers, they have also demonstrated that non-steroidal anti-
inflammatory agents may protect against several tumours as well as carcinogenesis 
(Mantovani, 2005). An example of this would be anti-inflammatory agents which suppress 
NF- κβ. Because NF- κβ is so active in tumour cells, supressing its activity could potentially 
have anti-cancer effects because this transcription factor is involved in the expression of many 
pro-inflammatory cytokines and factors which help to drive tumorigenesis in the context of 
cancer. If the expression of NF- κβ is down regulated by an anti-inflammatory drug, it may 
therefore inhibit tumour growth or carcinogenesis. 
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2.3.2.2 The link between Inflammation and oxidative stress in cancer 
Inflammation and oxidative stress work in synergy to perpetuate carcinogenesis and tumour 
progression in the context of cancer. While this topic is complex and has many contributing 
factors towards carcinogenesis, three main examples will be explained. 
Firstly, ROS may be produced following stimulus from pro-inflammatory cytokines in 
phagocytic and nonphagocytic cells via activation of certain kinases used for signalling. In 
phagocytes, NADPH oxidase is an enzyme used to remove bacterial or microbial invaders as 
part of the immune response. Once the phagosome becomes activated following interaction 
with an invading pathogen, superoxide free radicals accumulate within the phagosome, which 
are then converted to H2O2. This creates an acidic environment within the phagosome, 
allowing the invading pathogen to begin to break down and become destroyed. While this 
immune response is necessary for the survival of the host, the generation of the free radicals 
necessary to degrade pathogens may also have carcinogenic effects. In addition, TNF-α is 
associated with production of ROS via neutrophils, and along with IL-1β and interferon, also 
pro-inflammatory cytokines, may result in expression of nitric oxide synthase (Federico et al., 
2007). The elevated ROS production may also contribute to activation of transcription factors 
such as NF-κβ, which may activate many pro-inflammatory factors as well as promote cell 
proliferation during cancer initiation and progression (Laurent et al., 2005). 
Secondly, free radicals generated may react with the phospholipids found in cellular 
membranes, resulting in the formation of hydroperoxide and lipoperoxides (Marnett et al., 
2003).  This alters the properties of the membrane, particularly the membrane permeability, 
and causes lipid peroxidation to occur (Vernier, et al., 2009). Mutations to neighbouring 
epithelial cells can also occur due to the increase in free radicals produced through the 
peroxidation. This could result in the recruitment of inflammatory cells such as neutrophils to 
the site of lipid peroxidation, which in turn may result in an increase in free radicals, further 
perpetuating carcinogenesis. 
Thirdly, sustained inflammation in cancer is associated with angiogenesis, as explained 
previously. Macrophages and monocytes are a major source of angiogenic-promoting factors 
such as proinflammatory cytokines, NO, prostaglandins and VEGF (Zouki et al., 2001). These 
factors can induce the formation of ROS and contribute to the perpetuation of tumorigenesis 
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via angiogenesis. When arachidonic acid, found in the membranes of cells, undergoes 
oxidative metabolism, as described above, prostaglandins are generated, which in turn may 
induce the expression of pro-inflammatory cytokines, enhancing the production of ROS 
species (Baron and Sandler, 2000). COX-2 is one of the primary enzymes responding to the 
production of prostaglandins and are found to be upregulated in many different types of 
cancer, including breast carcinomas (Gupta and Dubois, 2001). 
From the literature reviewed here, the role of the self-propagating oxidative stress-
inflammation loop in cancer progression is undeniable.  Despite many decades of cancer 
research, no generally applicable effective therapy has been identified, perhaps due to the 
lack of these therapies to address these processes specifically.   Given the shift in consumer 
bias towards natural medicines, the next section provides a brief overview of progress made 
in terms of plant-derived natural medicines in the context of cancer treatment or prevention. 
 
2.4 Phytomedicine in cancer 
Biomedical or “Western” approaches to medicine are typically associated with the physical 
body of an individual, with treatment based on technology, science, clinical analysis and 
knowledge. This is quite different to that of traditional medicine, which may be defined as “ 
the sum total of all knowledge and practices, whether explicable or not, used in diagnosis, 
prevention and elimination of physical, mental, or societal imbalance, and relying exclusively 
on practical experience and observation handed down from generation to generation, 
whether verbally or in writing” (Richter, 2003). Although contrasting in approach, both play 
an imperative role in the field of medicine. 
In several countries worldwide, particularly those of low- and middle- income status, it has 
been found that the number of biomedical practitioners may not be enough to meet the 
needs of the population, showing the importance of traditional medicine as a health resource 
(Oyebode et al., 2016). It has been estimated that within South Africa alone, there are at least 
200 000 traditional healers, and only 25 000 biomedical doctors (Matomela, 2004). This 
almost 10:1 ratio demonstrates the fact that the South African population has a higher 
accessibility to these traditional healers, and therefore the important role these healers have 
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in addressing the physical and mental health needs of a large portion of the population 
(Morris, 2001).   
The main source of medication used and prescribed by these traditional healers are plant-
based and herbal remedies, with more than 770 plant species being traded and used in South 
Africa alone (Mander et al., 2007). Trade within this industry is said to contribute at least R29 
million to the economy each year, signifying just how essential this industry is (Mander et al., 
2007). However, not only are plant-based medications popular amongst traditional healers 
and their patients, they are also commercially more popular due to the increased consumer 
demand for phyto-pharmaceutical therapies (Patnala and Kanfer, 2012). Humans have been 
using products or materials from nature, such as plants, microorganisms and animals, as 
medication for different diseases for thousands of years. Increased demand for plant-based 
medicine has also been contributed to the fact that development of novel pharmaceutical 
medicines appears to be slowing down significantly, and thus over the last decade more focus 
has been placed on natural products and combining them with the high-throughput 
technology used in medicine today (Yuan et al., 2016). Plant-based therapies have several 
advantages over therapies based on biomedical treatments or pharmaceutical drugs, and one 
main example of this is the unique chemical range of plant-based products. This lends itself 
towards diversity in their mode of action, and potentially could allow for treatment in a wide 
array of diseases due to their multiple molecular targets. 
Within the context of cancer specifically, plant-based products have become an attractive 
alternative to traditional treatment, most commonly chemotherapy and radiation. Traditional 
therapies have been associated with many pitfalls such as high costs of treatment, secondary 
toxicity of anti-cancer drugs, and adverse drug reactions such as vomiting, pain, nausea, 
constipation, diarrhoea etc., which may require additional medical attention (Nurgali, et al., 
2018). Thus, the risk often outweighs the benefit when it comes to the use of traditional 
chemotherapeutic agents, which has resulted in many cancer sufferers to consider alternative 
therapies, one of which is the use of plant-based medication.  
Plant-based medications have been used for prevention and treatment of cancer for 
centuries, first seen in Africa, Asia and Europe centuries ago. Many plant extracts have been 
believed to prevent carcinogenesis, decrease tumour size and help prevent cancer-related 
symptoms (Greenwell and Rahman, 2015). Certain pure phytochemical extracts have already 
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been approved by the Food and Drug Administration (FDA) or have at least advanced to 
clinical trials for use as anti-cancer treatments, such as resveratrol obtained from grape skins, 
curcumin from turmeric, pomegranate extract, lycopene extracted from tomatoes, etc. (Paller 
et al., 2016). This illustrates the potential for use of plant-based therapies and phytochemicals 
for the prevention and treatment of cancer and is indicative of their ability to withstand 
scientific testing.  
In terms of common anti-cancer mechanisms of medicinal plants for which scientific data is 
available, a comprehensive review of medical plants used in cancer therapy has recently been 
published (Oyenihi and Smith, 2018). Some of the plants reviewed included Vitis vinifera 
(grapes), Curcuma longa (turmeric), Azadirachata indica (Indian lilac), Glycine max 
(soybeans), Olea europaea (olives), etc. It was demonstrated that these plants, among others 
reviewed, all had a high polyphenol content, and these plant-based polyphenol compounds 
are of the most prominence in the context of anti-cancer medication. A major advantage seen 
with the use of polyphenolic compounds is their ability to interact with multiple molecular 
targets (Kruger et al., 2014), and therefore make use of many different mechanisms of 
prevention or treatment of carcinogenesis. For the plants commonly used in cancer 
treatment, scientific data illustrates anti-inflammatory and/or antioxidant functioning for the 
majority. 
For the purpose of this thesis, I would like to focus on two specific plant-extracts which are 
commonly consumed in combination and which anecdotally have anti-cancer effects, namely 
Δ-7-mesembrenone (isolated from Sceletium tortuosum) and cannabidiol (CBD) (isolated 
from Cannabis sativa). 
 
2.4.1 Sceletium tortuosum 
This plant has many anecdotally claimed uses, including natural medicine, dietary 
supplements, raw materials, use in veterinary treatments, and pharmacology (Gericke and 
Viljoen, 2008). Sceletium is a small groundcover plant which is indigenous to South Africa, 
particularly the Western Karoo area (figure 2.5), belonging to the family of plants known as 
Mesembryanthemacae. Plants belonging to this family are distinguished by their dry leaves 
which appear to be “skeletonised” due to its pronounced lignified leaf vein structure, 
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accounting for the name Sceletium, deriving from the Latin word Sceletus (figure 2.6a) 
(Patnala and Kanfer, 2017). In addition to these dried-out leaves, Sceletium plants also have 
succulent leaves surrounding their flowers (figure 2.6b), whose petals may vary between 
white, light pink and yellow in colour. Currently, 8 species of the Sceletium plant are 
recognised, and can be divided into two “types” – the Tortuosum type and the Emarcidum 
type. The Tortuosum type includes: Sceletium tortusoum, Sceletium expansum, Sceletium 
crassicaule and Sceletium varians, while the Emarcidum type includes: Sceletium exalatum, 
Sceletium emarcidum and Sceletium rigidum (Patnala and Kanfer, 2017) Of these, Sceletium 
tortuosum has been used in natural products and has been studied the most extensively of 
the 8 species. 
 
Figure 2.5 – Geographical map indicating the distribution of Sceletium in South Africa (Gerike and Viljoen, 2008) 
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2.4.1.1 Sceletium and its alkaloids 
Traditionally, Sceletium tortusosum, also known as “Kanna” or “kougoed”, has been used for 
centuries by the San hunter-gatherers and the Nama population of Southern Africa, many 
years before the first uses of these plants by European settlers (Van Wyk, 2011). Historically, 
this plant has been used as a masticator for a variety of reasons, such as the anecdotal relief 
from hunger or thirst, relief from abdominal pain, relief from toothache, to treat colic in 
infants, and has even been said to have a sedative effect (Gericke and Viljoen, 2008).   
There are four different classes of alkaloids found within the Sceletium plants, namely, (1) the 
3a-aryl-cis-octahydroindole class, (2) the C-secomesembrine alkaloids, (3) the alkaloids 
containing a 2,3-disubstituted pyridine moiety and (4) a ring C-seco Sceletium alkaloid A4 
group (Gericke and Viljoen, 2008).   
Sceletium is currently one of the only known genus of plants with their species containing high 
levels of the alkaloid Mesembrine, one of the most pharmacologically-active alkaloids in this 
plant (Krstenansky, 2016). Sceletium tortuosum is known to contain mesembrine, 
mesembrenone, mesembranol, mesembrenol, alkaloid A4, chennanine and tortuosamine 
Figure 2.6a – Sceletium plant and its “skeletonised 
appearance” of the dried leaves (Gericke and 
Viljoen, 2008) 
Figure 2.6b – Sceletium tortuosum plant surrounded by its white 
flowers (Patnala and Kanfer, 2007) 
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(Gericke and Viljoen, 2008). It has been reported that only the tortuosum type of Sceletium 
plants contain these alkaloids, where as those of the emarcidum type are said to be totally 
void of mesembrine, or any other types of alkaloids associated with the species. The four 
major alkaloids that define the alkaloidal composition of Sceletium tortuosum are 
mesembrine ((3aS, 7aS)-3a-(3,4-dimethoxyphenyl)-1-1methylhexahydro-1H-indol-6(2H)-
one), mesembranol, ((3aS,6R,7aS)-3a-(3,4-dimethoxyphenyl)-1-methyloctahydro-1H-indol-6-
ol) mesembrenone ((3aR,7aS)-3a-(3,4-dimethoxyphenyl)-1-methyl-3,3a,7,7a-tetrahydro-1H-
indol-6(2H)-one) and mesembrenol ((3aR,6S,7aS)-3a-(3,4-dimethoxyphenyl)-1-methyl-
2,3,3a,6,7,7a-hexahydro-1H-indol-6-ol) (Shikanga et al., 2012; Krstenansky, 2017) (Figure 
2.8).  Sceletium tortuosum extracts differ in their potential for various medical treatments or 
preventative agents in accordance with their alkaloidal composition, and extracts higher in 
certain alkaloidal content have been found to have different medicinal properties. 
 
 
 
Figure 2.7 – The most abundant alkaloids found within Sceletium tortuosum (Chiu, et al., 2014) 
 
2.4.1.2 The alkaloidal content of Sceletium determines its properties 
Today, Sceletium tortuosum has a variety of uses, one of which is often to treat neurological 
disorders and neurodegeneration, due to its ability to suppress the central nervous system 
(Shikanga et al., 2012). Recently, it has been discovered that Sceletium tortuosum high in 
mesembrine alkaloid content acts primarily as a monoamine releasing agent (MRA) and has 
a secondary function as a selective serotonin reuptake inhibitor (SSRI), two of the most 
common classes of drugs used when treating anxiety and depression (Coetzee et al., 2015). 
Stellenbosch University  https://scholar.sun.ac.za
25 
 
Zembrin is a standardised extract of Sceletium tortuosum high in Mesembrine which has 
recently been identified as to interact with the Central Nervous System (CNS) through 
prevention of blockage of the Serotonin (5-HT) transporter and inhibition of 
phosphodiesterase-4 (PDE4) activity (Terburg et al., 2013). In this same study Zembrin was 
also shown to reduce anxiety-related amygdala reactivity and attenuate amygdala-
hippocampus coupling, both of which helping to reduce the hyper-responsivity to mild 
threats, as seen in anxiety sufferers. In addition to its potential anti-depressant effects, 
Zembrin has also shown potential benefit in the treatment of schizophrenia via dual targeting 
of both PDE4 activity and serotonin activity, resulting in improvement of the negative 
symptoms and cognitive deficits of schizophrenia (Chiu et al., 2017).  
In addition to its anxiolytic and anti-depressant effects, Sceletium tortuosum has been shown 
to have both mild anti-inflammatory, as well as potent antioxidant effects, depending on the 
alkaloidal content of the extract used. Firstly, Sceletium tortuosum containing a high 
mesembrine alkaloid content, known as TrimesemineTM, was shown to possess a mild anti-
inflammatory and cytoprotective effect in the context of acute inflammation in the peripheral 
compartment, ultimately resulting in increased monocytic cell viability and limited basal 
(unstimulated) production of pro-inflammatory cytokines (Bennett and Smith, 2018). A 
second Sceletium tortuosum extract, high in Δ-7 mesembrenone alkaloid content, was found 
to be a potent antioxidant, as it acted as a powerful inhibitor of tyrosinase activity, and had a 
similar effect on this enzyme as kojic acid at high doses (Bennett and Smith, 2018). The 
antioxidant activity of the Δ-7 mesembrenone extract was further corroborated by 
performing a 2,2-diphenyl-1-picrylhydrazyl (DPPH) inhibition assay in which the antioxidant 
capacity of Δ-7 mesembrenone was very similar to ascorbic acid, which is a well-known 
antioxidant (Allen and Bayraktutan, 2009). Finally, the polyphenol content of Δ-7 
mesembrenone was determined to be relatively high, 20-fold higher than the polyphenol 
content of TrimesemineTM (Bennett and Smith, 2018).  These studies highlight the potential 
different mechanisms and functions of Sceletium tortuosum extracts containing different 
alkaloidal compositions. These studies do however also illustrate the potential of Sceletium 
tortuosum as a supplement in the setting of inflammation related chronic disease, and the 
prospective prevention of these diseases through the mild anti-inflammatory and antioxidant 
Stellenbosch University  https://scholar.sun.ac.za
26 
 
mechanisms.  However, the potential anti-cancer efficacy of especially the potent antioxidant 
Δ-7 mesembrenone is still unknown. 
 
2.4.2 Cannabis sativa 
Cannabis sativa is an annual dioecious plant belonging to the family Cannabaceae (Fischedick 
et al., 2010). Cannabis sativa is possibly one of the oldest plants cultivated by man, but has 
remained controversial throughout its history. Cannabis sativa is a plant originating from 
central Asia and has gained popularity worldwide, cultivated in many different habitats and 
geographical regions (Merlin, 2003). For more than 5000 years, Cannabis has been used as a 
textile fibre, in traditional medicine, and as a source of food (Mikuriya, 1969).  Evidence 
suggests that many different cultural groups cultivated Cannabis sativa thousands of years 
ago, such as the Chinese, the Egyptians and the Romans (Mercuri et al., 2002). The plant 
arrived in India approximately 1000 years ago, and due to its narcotic properties, it was used 
in many religious rituals, as well as an anaesthetic (Fankhauser, 2002). 
Within Western medicine specifically, Cannabis had gained popularity as a medicinal plant 
during the 19th Century, and by early 20th Century, pharmaceutical companies had started 
producing several Cannabis-based medicinal products, such as Merck (Germany), Parke-Davis 
(USA), Burroughs-Wellcome (England) and Eli Lilly (USA) (Aldrich, 1997). These Cannabis 
products were prescribed by doctors for medical issues such as asthma, whooping cough, pain 
and as a sedative (Fankhauser, 2002). However, this eventually was stopped a few years later 
due to varying potencies of the Cannabis extracts, unpredictable responses across individuals, 
as well as side effects of anxiety and cognitive impairment (Zuardi et al., 2006).  In addition, 
it was during this time that other significant medical advancements were made, such as the 
development of certain vaccines, the emergence of aspirin and the development of 
hypodermic syringes which allowed for injection of drugs such as morphine (Li and Lin, 1974). 
However, for various reasons, Cannabis is still widely consumed for both recreational and 
medicinal applications. 
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2.4.2.1. Cannabinoids 
Phytocannabinoids are a group of terpenphenolic compounds predominantly produced in 
Cannabis. The most common and abundantly present cannabinoids within Cannabis sativa 
are Δ9-Tetrahydrocannabinol (Δ9-THC), Cannabidiol (CBD), Cannabinol (CBN), Cannabigerol 
(CBG), and Cannbichromene (CBC) (Andre et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.8 – The most abundant cannabinoids found within Cannabis sativa (Adapted, Palazzoli, 2017). 
 
Of these cannabinoids mentioned, Δ9-THC and CBD are the most commonly studied in the 
context of phytomedicine. Δ9-THC has been involved in many different medical experiments 
and has shown promising results in the context of a variety of medical diseases. An example 
of this is the therapeutic use of Δ9-THC in AIDS patients as an appetite stimulant, as well as to 
prevent disease-associated nausea and vomiting (Izzo et al., 2009). A Cannabis extract 
containing Δ9-THC and CBD in a ratio of 1:1, known as Sativex, has also been marketed and 
used for pain relief in patients with multiple sclerosis, and as an additional treatment in 
CBN 
CBG 
CBC 
CBD Δ9-THC 
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advanced cancer therapy (Russo, et al., 2007).  While Δ9-THC has a variety of benefits 
associated with its use, it is also the cannabinoid with the greatest psychotropic properties, 
and with this has been associated with a range of adverse side effects, such as memory loss, 
impaired brain function, psychosis, dizziness and dry mouth to name a few (McGee et al., 
2002; Ferguson et al., 2008). It is for this reason that the other non-psychotropic cannabinoids 
have gained interest and popularity within the context of plant-based medication and 
therapy. To date, CBD in particular has gained much popularity in the field of medicine and 
has shown to have potential in a variety of diseases, with no psycho-stimulating properties 
and very few known side effects (Pertwee, 2008; Zuardi, 2008).  
 
 2.4.2.2. Cannabidiol in cancer 
Within cancer specifically, there have been a variety of uses for Cannabis sativa. Preparations 
containing Δ9-THC and CBD have been used in cancer patients to help with an increase in 
appetite, to help treat nausea following chemotherapy, and to alleviate cancer-associated 
pain (Hall et al., 2005). However, given the adverse effects of whole Cannabis or Δ9-THC on 
for example memory, CBD has gained popularity as preferred medicinal Cannabis isolate.  
Cannabidiol has been shown to exert anti-proliferative as well as pro-apoptotic effects in a 
variety of human cancer cell lines, such as breast carcinoma, prostate carcinoma, gastric 
adenocarcinoma and colorectal carcinoma (Ligresti, et al., 2006). Furthermore, CBD has the 
potential to increase the production of ROS via the regulation of intracellular [Ca2+] in tumour 
cells, subsequently inducing apoptosis (Ryan, 2009). Treatment with CBD also resulted in the 
down-regulation in expression of Id-1, a gene involved in the regulation of the metastatic 
potential of cancer, thereby causing a reduction in the aggressiveness of the cancer 
(McAllister, 2007). Finally, and of most relevance to this study, Cannabidiol has been shown 
to act both as an anti-inflammatory and an antioxidant, thereby assisting in the prevention of 
initiation or progression of cancer (Turner, 1981). 
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2.4.2.3. CBD as an anti-inflammatory 
As mentioned previously, cancer is a chronic disease associated with chronic inflammation 
over a long period of time, and the resulting oxidative stress that comes with it. It would thus 
make sense that use of an anti-inflammatory agent could potentially alleviate the 
inflammatory load in the host and prevent cancer initiation or further progression of the 
disease. Studies have recently been conducted which suggest that Cannabis sativa, and more 
specifically CBD, can act as an anti-inflammatory agent and have immunosuppressive 
properties (Klein, 2005). In this study by Klein, it was shown that the endocannabinoid system 
is involved in host inflammatory response and plays a direct role in cytokine production and 
leukocyte formation. Further studies have indicated that CBD has the potential to decrease 
the production and expression of TNF-α, IL-6, IL-1β and IL-8, all pro-inflammatory cytokines 
in human and animal models (Mecholulam, 2007). This potential of CBD as a pro-
inflammatory cytokine mediator could be of great benefit within the context of cancer and 
alleviating the symptoms of inflammation. In addition to this, Cannabidiol may decrease 
inflammation via enhanced adenosine signalling mediated through inhibition of adenosine 
uptake (Burstein, 2015). It has been suggested in previous studies that adenosine A2A 
receptors may down-regulate immune cells that may be over active, resulting in a decline in 
the inflammatory response, and may be another mechanism through which CBD decreases 
inflammation. Finally, exposure to CBD in human and rat models has found a reduction in the 
immune response, whereby T-cell response and proliferation was suppressed and neutrophil 
migration was inhibited (Barichello et al., 2012). 
While inflammation related to cancer remains the focus of this study, the anti-inflammatory 
potential of CBD is also useful in the treatment and prevention of many other different 
diseases and disease-related symptoms. Recently, it was determined that CBD has potential 
anti-inflammatory benefits in the treatment of inflammation-related diseases such as 
Psoriasis, arthritis, Parkinson’s Disease, Alzheimer’s disease, Huntington’s disease and 
analgesia (Wilkinson and Williamson, 2007; Capasso et al., 2008; Costa, 2007).  
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2.4.2.4 CBD as an antioxidant 
In addition to its anti-inflammatory effects, Cannabidiol is also a potent antioxidant. CBD has 
been shown to have protective antioxidant activity similar to that of ascorbate or α-
tocopherol, both of which are well-characterised potent antioxidants (Hampson, 1998). 
Previous studies have demonstrated Cannabidiols ability to limit or inhibit glutamate toxicity 
mediated via its ability to reduce oxidative stress (Marsicano et al., 2002). In addition to this, 
when administered concurrently with binge ethanol consumption, CBD protected against 
oxidative stress-induced neurodegeneration with the same efficacy as α-tocopherol 
(Hamelink et al., 2005). Finally, further studies have shown that CBD has the capability to 
regulate the production of Ca2+ by the mitochondria, which may also mediate the production 
of ROS production and regulate intracellular oxidative stress levels (Ryan et al., 2009).  
 Study of the literature has therefore clearly indicated that Cannabidiol and other 
cannabinoids such as Δ9-THC may act as potent antioxidants, however little is known about 
the antioxidant effects of Cannabidiol within the context of cancer. This has set up the focus 
for this study, in order to better understand the antioxidant potential of Cannabidiol in the 
context of breast cancer treatment and prevention and to potentially elucidate the cellular 
mechanisms involved. 
 
2.5 Drug-Drug Interactions 
Medical drugs are chemical compounds which perform a biological function once ingested 
and incorporated into the body. These compounds mimic the behaviours and functions of 
certain biomolecules in order to carry out a physiochemical function, after which they are 
generally excreted. When two or more drugs are administered at the same time, they 
naturally will influence the function, duration and strength of their respective 
pharmacological actions via interaction with one another (Yoshikawa et al., 2004).  
Drug interactions may have desired, reduced or unwanted effects, and the incidence of drug-
drug interactions increases with increasing number of drugs administered at the same time. 
Possible drug-drug interactions include an additive effect, whereby administration of both 
medicinal drugs may increase the absorption and effect of each separate drug. This results in 
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a greater effectiveness of one or both drugs and is associated with a favourable treatment 
outcome. In contrast to this, drugs may also interact antagonistically to one another, resulting 
in a decrease in the function or uptake of one or both drugs. This may result in one or more 
of the drugs have a diminished function or a loss of function all together, an unfavourable 
outcome.  Finally, adverse drug reactions occur when two or more drugs are taken in 
combination, resulting in negative side effects when taken in combination to one another. 
These side effects have the potential to be dangerous and may result in hospitalisation or 
even death. Therefore, when administering two drugs simultaneously, it is important to study 
their interactions with one another and to determine the side effects of their concurrent use.  
 
2.6 Summary 
Cancer is a chronic, non-communicable disease responsible for 22% of deaths worldwide 
annually. While all cancers have their own set of unique triggers, carcinogenesis and tumour 
progression, most cancers are also associated with chronic inflammation and high levels of 
oxidative stress. Within breast cancer specifically, estrogen receptor status and oxidative 
stress levels have been linked to both carcinogenesis and progression of the disease. This has 
been thought to be due to the unresolved oxidative stress within ER+ cells, while ER- cells may 
resolve oxidative stress more efficiently. Within the context of cancer therapy, plant-based 
medicines could be promising therapeutic avenues, due to their high antioxidant and anti-
inflammatory modes of action, reducing the load of inflammation or oxidative stress and 
therefore either preventing or slowing cancer progression. Exposure of breast cancer cells to 
an antioxidant such as Δ-7-mesembrenone or Cannabidiol may result in cell death, and this 
could occur for a number of reasons. Firstly, an increase in antioxidant capacity within the cell 
may result in an increased ability to quench free radicals and subsequently a reduction in the 
oxidative stress levels, therefore preventing them from initiating carcinogenesis or preventing 
tumour progression. Alternatively, administration of an antioxidant at a dose too high may 
result in a shift towards a pro-oxidant status. This would cause the antioxidant to lose its 
radical scavenging ability and further drive oxidative stress. This may push the cell beyond its 
ability to survive the increased oxidative stress, resulting in cell death. Two plant-based 
extracts were investigated in this study, namely Δ-7 mesembrenone isolated from Sceletium 
tortuosum and Cannabidiol extracted from Cannabis sativa. These extracts were chosen due 
Stellenbosch University  https://scholar.sun.ac.za
32 
 
to their increase in popularity and consumption in the last decade, and because they are often 
used in conjunction with one another. We could find no literature published in the context of 
cancer-specific investigations for Δ-7 mesembrenone, and little experimental data exists in 
which the redox ability of Cannabidiol is described within the context of cancer specifically. 
This has set up the focus for this thesis, in order to better elucidate the redox capabilities of 
these two plant-based extracts within the context of breast cancer prevention or treatment.  
 
2.7 Hypothesis and aims 
2.7.1 Hypothesis 
We hypothesised that both Δ-7-mesembrenone from Sceletium tortuosum and Cannabidiol 
(CBD) from Cannabis sativa would have an anti-cancer effect when exposed to two breast 
cancer cell lines, MCF7 (ER+) and MDA-MB-231 (ER-).  
2.7.2. Aims  
In order to test our hypothesis, we formulated the following aims: 
a) To determine the effect of exposure with two plant-based extracts, namely Δ-7-
mesembrenone from Sceletium tortuosum and Cannabidiol from Cannabis sativa, in isolation 
and in combination, on normal breast cell (MCF12A) and breast cancer (MCF7 and MDA-MB-
231) cell viability. 
b) To elucidate cellular mechanisms related to redox status, by which these plant products 
may achieve their effects on cell survival. 
c) To assess potential interaction effects of the two plant extracts in this context. 
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CHAPTER 3: METHODS AND MATERIALS 
 
 3.1 Cell Culture 
The following cell lines were used for the purpose of this study: 
1. MCF12A – A non-tumorigenic epithelial cell line of normal mammary tissue 
2. MCF7 – Human breast cell adenocarcinoma (ER+, PR+, HER2-) 
3. MDA-MB-231 – Human breast cell adenocarcinoma (ER-, PR-, HER2-) 
Cultures of MCF12A, MCF7 and MDA-MB-231 cells were maintained at 37⁰C and 5% CO2 in a 
humidified incubator. MCF12A cells were maintained in DMEM-F12 medium (Lonza, 
Germany) supplemented with 10% FBS (Fetal Bovine Serum) (Gibco, Life Technologies Corp., 
USA), 100ng/mL cholera toxin (Sigma-Aldrich, USA), 500ng/mL hydrocortisone (Sigma-
Aldrich, USA) and 1mg/mL human insulin (Sigma-Aldrich, USA). MCF7 and MDA-MB-231 cells 
were maintained in high glucose DMEM (Gibco, USA) supplemented with 10% FBS (Gibco, Life 
Technologies Corp., USA).  
For each experiment, each cell line was exposed to a variation of doses of either Δ-7 
mesembrenone, CBD or a combination of the two extracts, for a period of 24 hours. After this 
exposure, the relevant experiments were carried out. Doses used for Δ-7 mesembrenone 
were 0.25mg/mL, 0.5mg/mL or 0.75mg/mL; and CBD doses were 5ng/mL, 10ng/mL, 20ng/mL 
or 100ng/mL. Doses used for the Δ-7 mesembrenone were selected based on 
recommendations by the supplier of the extract (Verve Dynamics, South Africa), and a 
preliminary study was conducted by our research group in order to determine the most 
effective doses of the extract within the context of this study. Cannabidiol doses were 
selected based on what was consistent with recent literature. Three combinations of the two 
were extracts were also used, namely 0.5mg/mL Δ-7-mesembrenone and 20ng/mL CBD 
(Combination 1); 0.75mg/mL Δ-7-mesembrenone and 20ng/mL CBD (Combination 2); and 
0.75mg/mL Δ-7-mesembrenone and 100ng/mL CBD (Combination 3). 
Cell numbers were determined before execution of each experiment by use of a 
haemocytometer following trypsinisation of each culture. Cells were seeded in 48 well plates 
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at a density of 50 000 cells per well for the trypan blue and XTT (Sodium 2,3,-bis(2-methoxy-
4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium) salt) assays, while 96 well 
plates were seeded at a density of 25000 cells per well for the ROS-Glo and GSH/GSSG assays.  
The trypan blue and XTT assays were performed in triplicate and a minimum of three times. 
ROS-Glo and GSH/GSSG assays were also performed in triplicate.  
 
 3.2 Characterisation of Sceletium tortuosum extract rich in Δ-7 mesembrenone and 
 Cannabidiol extracted from Cannabis sativa 
The Δ-7 mesembrenone rich extract was prepared from the Sceletium tortuosum plant, and 
this was selectively extracted to obtain approximately 60% Δ-7 mesembrenone alkaloidal 
content using proprietary methods (Verve Dynamics Pty, Somerset West, South Africa). The 
Cannabidiol, extracted from Cannabis sativa, was procured from Echo Pharmaceuticals B.V. 
(Weesp, Netherlands) after obtaining a permit from the Department of Health, Republic of 
South Africa (Permit No: POS 231/2017/2018). Both extracts were kindly donated by Mr 
Richard Davies (Verve Dynamics Pty, Somerset West, South Africa) for the purpose of this 
study. 
High-performance Liquid Chromatography (HPLC) was employed to further characterize both 
the Δ-7 mesembrenone and Cannabidiol extracts. The Shimadzu HPLC system equipped with 
LC-10AT single pump and SPD-10A UV-VIS detector as well as a Luna 5 µm, C18 (2) 100Å, 150 
x 4.6 mm column (Phenomenex, California, USA) was used. Products were dissolved in HPLC-
grade absolute methanol and filtered with 0.45 µm syringe filter before separations were 
carried out under isocratic conditions. A mobile phase containing absolute methanol: glacial 
acetic acid: deionized water (70%:15%:15%) was used for the Cannabidiol extract; and that 
containing deionized water: acetonitrile (70%:30%) + 1 mL/L aqueous ammonia was used for 
the Δ-7-mesembrenone extract. The flow rate was set at 1 mL/L; detector wavelength at 250 
nm; and temperature maintained at 25 0C for the 15 minutes run time of the Cannabidiol 
extract. For the Δ-7-mesembrenone extract analysis, the flow rate was also set at 1 mL/L; 
detector wavelength at 280 nm; temperature at 25 0C for the 14 minutes run time. 20 µL of 
each sample was injected for both extracts. 
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3.3 XTT mitochondrial reductive capacity assay 
The XTT assay was used to determine the effects of the Δ-7-mesembrenone, CBD or the 
various combination doses on the mitochondrial reductive capacity of each cell line, which 
could then be used to obtain a better understanding of the viability of each cell type following 
exposure. In brief, MCF7, MCF12A and MDA-MB-231 cells were exposed to either Δ-7-
mesembrenone, CBD or combination dosages for a period of 24 hours. At the end of the 
incubation period, media and extracts were removed, and the tetrazolium dye, sodium 2,3,-
bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium) salt (XTT) 
was added to each well at a concentration of 10mg/mL. An intermediate electron carrier, N-
methyl dibenzopyrazine methyl sulfate (PMS), was then added to each well at a concentration 
of (20µL/mL), to assist with reduction of XTT to a highly pigmented formazan product, as first 
described (Scudiero et al., 1988). Cells were then incubated for 4 hours at 37⁰C in a 5% CO2 
humidified incubator. The absorbance of each well was then determined at 490nm, and 
results were expressed as a percentage of the control for each respective cell line.  
 
3.4 Trypan blue cell viability assay 
Absolute cell viability was determined using the trypan blue assay as more direct measure of 
cell viability, to further corroborate results seen in the XTT assay. Each cell type was seeded 
in 48 well plates at 50000 cells per well and was allowed to grow and adjust for a period of 24 
hours. Following this, cells were exposed to the respective doses of either Δ-7-
mesembrenone, CBD or a combination of the two extracts for a period of 24 hours. Cells were 
then trypsinised from the wells, the trypan blue azo dye (Thermo Fisher, USA) was added to 
each sample and 10µl dyed cell suspension loaded into Countess counting chamber slides. 
Cell viability was subsequently determined using the Countess automated cell counter 
(Thermo Fisher, USA). The final cell viability was expressed as a percentage of the control for 
each cell type.  
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 3.5 ROS-Glo H2O2 assay  
Reactive Oxygen Species (ROS) are generated in all cells and may act as molecules for 
signalling, however in excess they may lead to cell damage or even cell death. Therefore, 
measuring ROS production would give a good indication as to what events were occurring 
within the different cells following exposure to the various extracts and combinations. The 
ROS-Glo H2O2 assay (Promega, USA) was used to determine the amount of H2O2 generated 
within the cells, as many types of ROS are converted into H2O2 (Alfadda and Sallam, 2012). 
Thus, a change in H2O2 may indicate a shift in the ROS levels being generated within the 
different cell types. This assay was performed after the MCF7, MCF12A and MDA-MB-231 
cells were exposed to either Δ-7-mesembrenone, CBD or combination dosages for a period of 
18 hours. A H2O2 substrate was then added to each well and incubated for a further 6 hours 
at 37⁰C in a 5% CO2 humidified incubator. This H2O2 substrate reacts with H2O2 to generate a 
luciferin precursor. In the final step, a ROS-Glo detection solution buffer was added, which 
contained Ultra-GloTM Recombinant luciferase as well as D-Cysteine, and was incubated for 
20 minutes. The D-Cysteine serves to convert the luciferin precursor to luciferin, following 
which the Ultra-GloTM recombinant luciferase reacts with the luciferin to generate a 
luminescent signal in proportion with the H2O2 generated. This luminescent signal was read 
using a Glo-Max luminometer (Promega, USA). Results were expressed as Relative Light Units 
(RLU).  
 
 3.6 GSH/GSSG-Glo assay 
Glutathione is present in all eukaryotic cells and serves as an abundant antioxidant source 
(Sies, 1999). Most Glutathione is found as its reduced form, GSH, whereby the sulfhydryl 
group of the cysteine is not linked to a second Glutathione. Small amounts of Glutathione 
exist in its oxidised form, GSSG, and is present as a dimer of two molecules linked through a 
disulphide bond between the two cysteine groups on both molecules (Pompella, 2003). 
Glutathione that has been oxidised is indicative of oxidative stress, and a decrease in the ratio 
between GSH and GSSG is associated with aging, chronic disease and certain signalling events 
between cells (Ghezzi, 2005). Thus, determining the ratio of GSH:GSSG in all cell types 
following exposure to either Δ-7-mesembrenone, CBD or combination exposures would give 
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a good indication of the level of oxidative stress occurring within the various cell types, as well 
as the antioxidant capacities of the different cell lines. The GSH/GSSG-Glo assay (Promega, 
USA) was used to quantify the total amount of Glutathione within the cells (GSH and GSSG), 
as well as the amount of oxidised Glutathione, and a ratio was then calculated from these 
readings. Briefly, MCF7, MCF12A and MDA-MB-231 cells were exposed to either Δ-7-
mesembrenone, CBD or combination dosages for a period of 24 hours. Following the 
incubation period, media and extracts were removed, and either Total Glutathione Lysis 
Reagent (GSH+GSSG) or Oxidised Glutathione Lysis Reagent (GSSG) was added to the cells. 
The Total Glutathione Lysis reagent lysed the cells and converts all Glutathione present in 
those cells to its reduced form, GSH. In contrast, the Oxidised Glutathione Lysis reagent lysed 
the cells and released the GSH and GSSG present in the cells, but it also contains N-
Ethylmaleimide, which reacts with GSH specifically and prevents it from generating a 
luminescent signal.  A Luciferin generation agent was subsequently added to all cells and 
incubated on a shaker at room temperature for 30 minutes. This generation agent creates 
one mole of luciferin from the GSH probe, and two moles of luciferin per GSSG probe. Finally, 
Luciferin Detection agent was added to all of the cells and incubated for a further 15 minutes 
on a shaker at room temperature. The detection agent stops the generation of luciferin and 
creates a luminescent signal which is proportional to the amount of GSH from the total 
Glutathione (GSH+GSSG), or to GSSG only. The luminescence of each well was read using a 
Glo-Max luminometer, and GSH:GSSG ratios calculated from the Relative Light Units (RLUs).  
 
 3.7 Statistical Analysis 
All statistical analyses were conducted using Graphpad Prism Version 6 software (Graphpad 
software, La Jolla, CA, USA), and results were expressed as the mean ± SD. Two-way ANOVAs 
were used, as well as Bonferroni post-hoc tests, in order to elucidate any differences seen 
between the cell types and the different dosages of the relevant extract used. Differences 
between groups and dosages were considered statistically significant at P<0.05. 
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CHAPTER 4: RESULTS 
 
4.1 Characterisation of Δ-7-mesembrenone extract from Sceletium tortuosum and 
Cannabidiol extract from Cannabis sativa 
The Δ-7-mesembrenone product extracted from Sceleitum tortusoum was analysed using 
HPLC methods to determine the polyphenol content of the extract. As depicted in Figure 4.1, 
there are 3 main peaks seen on the chromatogram, which represent Δ-7-mesembrenone, 
mesembrenone and mesembrine respectively. Quantitatively,  62.2% of this extract was 
comprised of the Δ-7-mesembrenone alkaloid, while 27.9%  was made up of mesembrine and 
9.8% mesembrenone. This demonstrates the Δ-7-mesembrenone rich composition of the 
extract used in this study.  
 
Figure 4.1 – Chromatogram indicating the polyphenol content of the Δ-7-mesembrenone 
extract obtained from Sceletium tortuosum 
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The Cannabidiol extract from Cannabis sativa was also analysed using HPLC methods used for 
the Δ-7-mesembrenone product. As illustrated in Figure 4.2, there is 1 peak on the 
chromatogram, representing 100% Cannabidiol content of this extract. 
 
Figure 4.2 – Chromatogram indicating that the Cannabidiol product extracted from Cannabis 
sativa is 100% CBD 
 
4.2 Effects of Δ-7-mesembrenone, CBD or combination treatments on cytotoxicity of 
MCF12A, MCF7 and MDA-MB-231 cell models 
The Trypan Blue cell viability assay was used to determine the cytotoxicity encountered by 
the MCF12A, MCF7 and MDA-MB-231 cell models following exposure to Δ-7-mesembrenone, 
CBD or combinations of both extracts. Following exposure to Δ-7-mesembrenone, the 
MCF12A cell line experienced a statistically significant dose-dependent decrease in absolute 
cell viability across all doses of Δ-7-mesembrenone (Figure 4.3). Both MCF7 and MDA-MB-231 
cell types also experienced a statistically significant decrease in cell viability for the two 
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highest doses of Δ-7-mesembrenone (0.5mg/mL and 0.75mg/mL). The MDA-MB-231 cell line 
experienced a larger decrease in cell viability in comparison to control than that of the MCF7 
cell line. Following performance of a two-way ANOVA, the main effect of dose had a 
significance value of P<0.001.  
 
Figure 4.3 – Cell viability of MCF12A, MCF7 and MDA-MB-231 following treatment with increasing doses of Δ-
7-mesembrenone. The data are presented as a percentage of the untreated controls for each cell type. Doses 
used were 0.25mg/mL, 0.5mg/mL and 0.75mg/mL. Statistics were obtained in the form of a two-way ANOVA 
and a Bonferroni post-hoc test (** = P<0.01; *** = P<0.001). 
 
Cell viability of the three cell types was then determined following exposure to CBD at four 
different doses (Figure 4.4). Statistically significant cytotoxicity was only observed at the two 
highest doses of CBD (20ng/mL and 100ng/mL) for the MCF12A and MCF7 cell lines, and only 
at the highest dose (100ng/mL) in the MDA-MB-231 cell line. Results of the two-way ANOVA 
indicated a main effect of dose significance value of P<0.001.  
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Figure 4.4 – Cell viability of MCF12A, MCF7 and MDA-MB-231 following treatment with increasing doses of 
CBD. The data are presented as a percentage of the untreated controls for each cell type. Doses used were 
5ng/mL, 10ng/mL, 20ng/mL and 100ng/mL. Statistics were obtained in the form of a two-way ANOVA and a 
Bonferroni post-hoc test (** = P<0.01; *** = P<0.001). 
 
Finally, cell viability was determined following exposure to three different combinations of Δ-
7-mesembrenone and CBD (Figure 4.5). For the MCF12A and MDA-MB-231 cell lines, 
significant decreases in cell viability was observed in combination 2 (0.75mg/mL Δ-7-
mesembrenone, 20ng/mL CBD) and combination 3 (0.75mg/mL Δ-7-mesembrenone, 
100ng/mL CBD).  The MCF7 cell line appeared to be more susceptible to combination 
treatments, with significant decreases in viability observed across all combination treatments. 
Following assessment using a two-way ANOVA, main effect of combination doses was 
P<0.001. 
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Figure 4.5 – Cell viability of MCF12A, MCF7 and MDA-MB-231 following treatment with 3 different 
combinations of Δ-7-mesembrenone and CBD. The data are presented as a percentage of the untreated 
controls for each cell type. Combinations used are 0.5mg/mL Δ-7-mesembrenone and 20ng/mL CBD (1); 
0.75mg/mL Δ-7-mesembrenone and 20ng/mL CBD (2); and 0.75mg/mL Δ-7-mesembrenone and 100ng/mL CBD 
(3). Statistics were obtained in the form of a two-way ANOVA and a Bonferroni post-hoc test (* = P<0.05; ** = 
P<0.01; *** = P<0.001). 
 
4.3 Effects of Δ-7-mesembrenone, CBD or combination treatments on the 
mitochondrial reductive capacity of MCF12A, MCF7 and MDA-MB-231 cell models 
The XTT assay was used to determine the mitochondrial viability of the MCF12A, MCF7 and 
MDA-MB-231 cell lines following treatment with either Δ-7-mesembrenone, CBD or a 
combination of the two. Once again, following exposure to Δ-7-mesembrenone, the MCF12A 
cell line displayed a statistically significant dose-dependent decrease in mitochondrial 
reductive capacity for all doses of Δ-7-mesembrenone tested (Figure 4.6). The MCF7 cell type 
also exhibited the same dose- dependent, statistically significant decrease in reductive 
capacity across all Δ-7-mesembrenone doses, and experienced a slightly greater decrease in 
reductive capacity than the MCF12A cells. The MDA-MB-231 cells only experienced a 
statistically significant decrease in mitochondrial reductive capacity at the highest dose of Δ-
7-mesembrenone (0.75mg/mL). The main effect of dose assessed using a two-way ANOVA 
once again had a statistical significance of P<0.001. 
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Figure 4.6 – Mitochondrial reductive capacity of MCF12A, MCF7 and MDA-MB-231 following treatment with 
increasing doses of Δ-7-mesembrenone. The data are presented as a percentage of the untreated controls for 
each cell type. Doses used were 0.25mg/mL, 0.5mg/mL and 0.75mg/mL. Statistics were obtained in the form of 
a two-way ANOVA and a Bonferroni post-hoc test (** = P<0.01; *** = P<0.001). 
 
A statistically significant  reduction in mitochondrial viablity was seen in MCF12A cells only at 
the highest dose of CBD (100ng/mL) (Figure 4.7). However, in the MCF7 cell line, a decrease 
in reductive capacity was observed at the two highest doses, and experienced a greater 
reduction in this reductive capacity compared to that seen in the MCF12A cell line. In contrast 
to this, the MDA-MB-231 cells experienced a significant dose-dependent increase in 
mitochondrial reductive capacity at 10ng/mL and 20ng/mL CBD, with this reductive capacity 
appearing to return to approximately the same as the control at the highest dose of CBD. 
Main effect of dose was statistcally significant (P<0.001) according to the results of the two-
way ANOVA. 
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Figure 4.7 – Mitochondrial reductive capacity of MCF12A, MCF7 and MDA-MB-231 following treatment with 
increasing doses of CBD. The data are presented as a percentage of the untreated controls for each cell type. 
Doses used were 5ng/mL, 10ng/mL, 20ng/mL and 100ng/mL. Statistics were obtained in the form of a two-way 
ANOVA and a Bonferroni post-hoc test (*** = P<0.001). 
 
The combination doses yielded results similar to those seen in the trypan blue viability data. 
The MCF12A cells experienced a significant reduction in mitochondrial viability for both 
combinations 2 and 3, while the MCF7 cell line experienced a decrease in mitochondrial 
reductive capacity across all 3 combinations (Figure 4.8). The MDA-MB-231 cells experienced 
a statistically significant increase in mitochondrial reducitve capacity when exposed to 
combination 2, and a statistically significant decrease in reductive capacity when exposed to 
combination 3. A statistically significant effect of combination used was determined using a 
two-way ANOVA, and a P value less than 0.001 was obtained. 
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Figure 4.8 – Mitochondrial reductive capacity of MCF12A, MCF7 and MDA-MB-231 following treatment with 
3 different combinations of Δ-7-mesembrenone and CBD. The data are presented as a percentage of the 
untreated controls for each cell type. Combinations used are 0.5mg/mL Δ-7-mesembrenone and 20ng/mL CBD 
(1); 0.75mg/mL Δ-7-mesembrenone and 20ng/mL CBD (2); and 0.75mg/mL Δ-7-mesembrenone and 100ng/mL 
CBD (3). Statistics were obtained in the form of a two-way ANOVA and a Bonferroni post-hoc test (* = P<0.05; 
** = P<0.01; *** = P<0.001). 
 
4.4 Determination of ROS production in MCF12A, MCF7 and MDA-MB-231 cell 
models following exposure to Δ-7-mesembrenone, CBD or combination treatments  
ROS production was determined using the ROS-Glo H2O2 assay from Promega in each cell type 
following treatment with either Δ-7-mesembrenone, CBD or a combination of both extracts. 
ROS production increased significantly in a dose-dependent manner for both MCF12A and 
MCF7 cell lines for all Δ-7-mesembrenone doses assessed (Figure 4.9). There was no 
statistically significant increase in ROS production seen in the MDA-MB-231 cell line for any 
of the Δ-7-mesembrenone doses assessed. Main effect of dose assessed using a two-way 
ANOVA was significant, with P<0.001. 
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Figure 4.9 – ROS production of MCF12A, MCF7 and MDA-MB-231 following treatment with increasing doses 
of Δ-7-mesembrenone. The data are presented as relative light units determined using a Glo-Max luminometer. 
Doses used were 0.25mg/mL, 0.5mg/mL and 0.75mg/mL. Statistics were obtained in the form of a two-way 
ANOVA and a Bonferroni post-hoc test (*** = P<0.001). 
 
When exposed to CBD, the MCF12A cells showed a dose-dependent decrease in ROS 
production when compared to the control, which reached statistical significance for the two 
highest doses of CBD (20ng/mL and 100ng/mL) (Figure 4.10). A similar effect was seen in the 
MDA-MB-231 cell line, with ROS production significantly reduced at the 10ng/mL and 
20ng/mL doses, although in this cell line, ROS production appeared to increase to control 
levels after exposure to the 100mg/mL dose. In contrast, the MCF7 cells exhibited a dose-
dependent increase in production of ROS, which reached statistically significance at 20ng/mL 
and 100ng/mL doses of CBD. Results of a two-way ANOVA indicated that the main effect of 
dose had a significance of P<0.001. 
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Figure 4.10 – ROS production of MCF12A, MCF7 and MDA-MB-231 following treatment with increasing doses 
of CBD. The data are presented as relative light units determined using a Glo-Max luminometer. Doses used 
were 5ng/mL, 10ng/mL, 20ng/mL and 100ng/mL. Statistics were obtained in the form of a two-way ANOVA and 
a Bonferroni post-hoc test (** = P<0.01; *** = P<0.001). 
 
Exposure to combination doses of Δ-7-mesembrenone and CBD resulted in similar ROS 
production trends in all 3 cell types as that of the Δ-7-mesembrenone alone (Figure 4.11). The 
MCF12A and MCF7 cell lines both experienced significant increases in ROS production for all 
3 combinations tested. In line with the Δ-7-mesembrenone results, the MDA-MB-231 cells 
seemed relatively less sensitive to the combination treatments, with ROS production only 
significantly increased after exposure to combination 3. Main effect of combination, 
determined using a two-way ANOVA, was statistically significant (P<0.001). 
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Figure 4.11 – ROS production of MCF12A, MCF7 and MDA-MB-231 following treatment with 3 different 
combinations of Δ-7-mesembrenone and CBD. The data are presented as relative light units determined using 
a Glo-Max luminometer. Combinations used are 0.5mg/mL Δ-7-mesembrenone and 20ng/mL CBD (1); 
0.75mg/mL Δ-7-mesembrenone and 20ng/mL CBD (2); and 0.75mg/mL Δ-7-mesembrenone and 100ng/mL CBD 
(3). Statistics were obtained in the form of a two-way ANOVA and a Bonferroni post-hoc test (** = P<0.01; *** 
= P<0.001). 
 
4.5 Determination of the ratio of reduced to oxidised glutathione in MCF12A, MCF7 
and MDA-MB-231 cell models following exposure to Δ-7 mesembrenone, CBD or 
combination treatments  
The ratio of reduced Glutathione (GSH) to oxidised Glutathione (GSSG) was determined using 
the GSH/GSSG-Glo assay from Promega in order to assess antioxidant capacity of the cell 
types. A statistically significant decrease in the GSH/GSSG ratio was only observed for the 
MCF7 cell type at the highest dose of Δ-7-mesembrenone (Figure 4.12). There were no 
significant differences in the GSH/GSSG ratio for MCF12A and MDA-MB-231 cell types across 
all Δ-7-mesembrenone doses assessed. A two-way ANOVA was performed, and main effect 
of dose was P<0.05. 
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Figure 4.12 – GSH/GSSG ratio of MCF12A, MCF7 and MDA-MB-231 following treatment with increasing doses 
of Δ-7-mesembrenone. The data are presented as a ratio determined using a standard curve after raw data was 
determined using a Glo-Max luminometer. Doses used were 0.25mg/mL, 0.5mg/mL and 0.75mg/mL. Statistics 
were obtained in the form of a two-way ANOVA and a Bonferroni post-hoc test (*** = P<0.001). 
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CBD exposure resulted in a significant decrease in the GSH/GSSG ratio in the MCF12A and 
MCF7 cells at the highest dose of CBD (Figure 4.13). No significant changes were observed in 
this ratio in the MDA-MB-231 cells following exposure to CBD. Main effect of dose was 
assessed using a two-way ANOVA and had a P value less than 0.001.  
 
 
Figure 4.13 – GSH/GSSG ratio of MCF12A, MCF7 and MDA-MB-231 following treatment with increasing doses 
of CBD. The data are presented as a ratio determined using a standard curve after raw data was determined 
using a Glo-Max luminometer. Statistics were obtained in the form of a two-way ANOVA and a Bonferroni post-
hoc test (*** = P<0.001). 
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Finally, MCF12A cells exhibited significant, decreases in the GSH/GSSG ratios for all 3 
combination doses (Figure 4.14). The MCF7 cells showed a decrease in GSH/GSSG ratios that 
was statistically significant for combinations 2 and 3. A two-way ANOVA indicated that the 
effect of different combinations used was statistically significant (P<0.001). Again, the MDA-
MB-231 cells showed no significant difference in the GSH/GSSG ratios in response to any of 
the combinations assessed. 
 
 
Figure 4.14 – GSH/GSSG ratio of MCF12A, MCF7 and MDA-MB-231 following treatment with 3 different 
combinations of Δ-7-mesembrenone and CBD. The data are presented as a ratio determined using a standard 
curve after raw data was determined using a Glo-Max luminometer. Combinations used are 0.5mg/mL Δ-7-
mesembrenone and 20ng/mL CBD (1); 0.75mg/mL Δ-7-mesembrenone and 20ng/mL CBD (2); and 0.75mg/mL 
Δ-7-mesembrenone and 100ng/mL CBD (3). Statistics were obtained in the form of a two-way ANOVA and a 
Bonferroni post-hoc test (* = P<0.05; ** = P<0.01; *** = P<0.001). 
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CHAPTER 5: DISCUSSION 
 
Δ-7 mesembrenone, isolated from Sceletium tortuosum, and Cannabidiol, extracted from 
Cannabis sativa, used in isolation or in combination, was studied in the context of their effect 
on cellular oxidative stress and survival in an in vitro cancer model.  
We report differential effects for the two extracts assessed. While Δ-7 mesembrenone 
seemed to exhibit more adverse than beneficial effects, cannabidiol data were more positive. 
 
5.1 Δ-7 mesembrenone in isolation exhibited high risk for toxicity  
In terms of the anti-cancer capacity of Δ-7 mesembrenone in MCF12A, MCF7 and MDA-MB-
231 cells at three different doses (0.25-, 0.5-, and 0.75mg/mL), cytotoxicity was evident in the 
MCF12A and MCF7 cell lines across all doses of Δ-7 mesembrenone, while the MDA-MB-231 
cells had a reduction in cell viability only at the highest doses of Δ-7 mesembrenone. A similar 
trend was also observed when examining the mitochondrial reductive capacity of the cells 
following exposure to Δ-7 mesembrenone.  
While Δ-7 mesembrenone is an antioxidant, exposure to an antioxidant at a dose that is too 
high may also be detrimental to the cells. This may result in a reduction in their ability to 
scavenge free radicals, shifting the antioxidant to a pro-oxidant, further exacerbating the 
problem of oxidative stress (Burkitt, 2001). However, it is also known that cancer cells have 
been associated with a naturally higher level of ROS and oxidative stress than non-cancerous 
cell types and increased ROS has a direct link to both the initiation and propagation of the 
tumour as explained previously. Therefore, cancer cells may potentially survive increased 
levels of oxidative stress with a greater efficiency than that of other types of normal human 
cells (Trachootham et al., 2006). With this in mind, the relevant cellular mechanisms at play 
following exposure of the three cell lines to Δ-7 mesembrenone may be elucidated.  
Firstly, in comparison to that of the other two cell lines, the MCF12A cells experienced the 
greatest decrease in cell and mitochondrial viability. This cell death may be explained by the 
high levels of ROS production experienced following treatment with this extract, indicating 
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that Δ-7 mesembrenone acted as a pro-oxidant in these cells. There appeared to be little 
glutathione antioxidant activity, and endogenous antioxidant capacity was unable to reduce 
the effects of the high levels of oxidative stress. 
Secondly, cytotoxicity was experienced at the highest doses of Δ-7 mesembrenone assessed 
in the MCF7 cell model, with reductions in the mitochondrial reductive capacity seen across 
all doses. This translated into an increased ROS production across all doses assessed, once 
again demonstrating the pro-oxidant activity of Δ-7 mesembrenone in these cells. 
Endogenous glutathione antioxidant capacity was also decreased in the MCF7 cells, 
potentially illustrating a greater endogenous antioxidant capacity than that of the MCF12A 
cells, and the innate ability of cancer cells to tolerate oxidative stress at a higher level than 
non-cancerous cells, consistent with the findings of many studies (Pelicano, 2004; Cairns et 
al., 2011; Gupte et al., 2008; Hileman et al., 2003).  
Finally, within the MDA-MB-231 cells, cytotoxicity and mitochondrial toxicity was only 
experienced at the highest doses of Δ-7 mesembrenone assessed, with no changes in ROS 
production or endogenous antioxidant activity. This can be explained by the increased 
tolerance of cancer cells to ROS, as mentioned previously. In addition to this, the MDA-MB-
231 cell line is the only cell line assessed in this study which does not express the estrogen 
receptor (ER-). Previous studies (Mobley and Brueggemeier, 2004; Liehr, 1999; Wani et al., 
1998) have indicated that cells that are ER- have a greater ability to metabolise free radicals 
and reduce oxidative stress, while the presence of estrogen receptors increase the sensitivity 
to oxidative stress.  
From these findings it is clear that in terms of breast cancer therapy, any potential anti-cancer 
benefit of Δ-7 mesembrenone is outweighed by the risk to normal cells associated with its 
exposure. No literature currently exists about Δ-7 mesembrenone, except that it is a very 
potent antioxidant (Bennett and Smith, 2017). Much lower doses of Δ-7 mesembrenone may 
be assessed in the context of an antioxidant supplement, however, toxicity associated with 
its exposure in normal cells rules it out as a potential cancer treatment. It is also important to 
note that this study was conducted in vitro and may not translate directly to in vivo models. 
However, doses selected for this study were relevant to work previously conducted using Δ-
7 mesembrenone (Bennet and Smith, 2017), and due to the cytotoxicity experienced in the 
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normal cells even at the lowest dose, use of different doses would not be relevant in this 
context. 
5.2 Cannabidiol may provide anti-cancer benefits in certain types of breast cancer 
In contrast to the poor prognostic value of Δ-7 mesembrenone, data for Cannabidiol seems 
more positive. Firstly, in terms of the normal breast cell line, reductions in cell viability and 
mitochondrial reductive capacity only occurred significantly at the highest dose assessed. 
However, exposure to higher doses of CBD (20- or 100ng/mL) resulted in a decrease in the 
ROS production in this cell type, which could be explained by the antioxidant potential of 
Cannabidiol (Hampson, 1998; Mariscano et al., 2002). While high concentrations of free 
radicals may damage cells and result in cell death, a certain concentration of free radicals are 
important for cell metabolism (Droge, 2002). If too many free radicals are quenched, effects 
may be detrimental to the cells. This may be the case here, in which Cannabidiol is very 
potent, resulting in a decrease in reactive species that actually becomes detrimental to the 
cells at the highest dose of 100ng/mL CBD. Finally, endogenous antioxidant capacity of the 
MCF12A cell line was exhausted at 100ng/mL of CBD, which may suggest that the Cannabidiol 
loses its beneficial effects and pattern of drug response at a certain threshold, and this may 
require further investigation.   
When considering results in MCF7 cells exposed to CBD cell viability and mitochondrial 
reductive capacity were both decreased significantly at the highest doses assessed. This 
reduction in mitochondrial reductive capacity was more severe than the one seen in the 
MCF12A cell line and was associated with large increases in ROS production. There are several 
reasons as to why this may occur in the MCF7 cell line. Firstly, this cell line is estrogen receptor 
positive, as previously mentioned, and has an increased sensitivity to reactive species. 
Secondly, literature has indicated that MCF7 cells specifically experienced a decrease in cell 
proliferation upon exposure to Cannabidiol (Caffarel et al., 2012). This study indicated that 
cell cycle progression in MCF7 cells is arrested, and transition from the G1 to the S phase is 
inhibited, in conjunction with inhibition of adenyl cyclase expression, resulting in the 
activation of Raf-1/ERK/MAPK cascade, ultimately downregulating prolactin expression 
(Nisson et al., 2011). This effectively prevents cell proliferation in the MCF7 cell line 
specifically. Thirdly, additional studies have also implicated CBD exposure in increased ROS 
production in certain tumour cell lines specifically, mediated via increased intracellular [Ca2+] 
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controlled by inhibition of mitochondrial Ca2+ reuptake or increased release of Ca2+ (Izzo et 
al., 2009). Interestingly, additional studies have indicated that metabolism of CBD in certain 
tumour cells results in formation of an intermediate known as CBD hydroxyquinone, which 
also generates ROS and contributes to cytotoxicity (Wu and Yan, 2010). This is of interest 
when considering the reduction in the GSH/GSSG ratio of the MCF7 cells following CBD 
exposure (figure 4.12), as CBD hydroxyquinone has been recently observed to form a complex 
with endogenous glutathione, resulting in glutathione depletion (Wu and Yan, 2010). This 
provides an explanation for the significantly greater decrease in endogenous glutathione in 
the MCF7 cell line following CBD exposure when compared to the normal control cells. 
Additionally, endogenous glutathione may also have been depleted via scavenging of 
increased reactive species generated in this cell line.  
A very different result was found upon exposure of the MDA-MB-231 cells to the CBD extract. 
Cytotoxicity was only experienced at the highest dose, and mitochondrial reductive capacity 
increased at doses of 10- and 20ng/mL CBD, with reductions in reductive capacity only 
experienced at the highest dose. This could be indicative of the CBD acting as an antioxidant, 
removing free radicals and allowing for better signalling, proliferation and survival of the 
MDA-MB-231 cells. Similar to the MCF12A cells, the MDA-MB-231 cell model experienced a 
significant decrease in ROS production at 10- and 20ng/mL CBD doses, with ROS levels 
appearing to return to normal at the 100ng/mL dose. This could be explained by the CBD 
offering a protective effect mediated via free radical removal and decreases in oxidative stress 
to a level more beneficial to the cell. The lack of estrogen receptors also allows MDA-MB-231 
cells to better metabolise reactive species, as previously discussed. Finally, no changes were 
observed in the ratio between GSH and GSSG, which is in line with decreased production of 
ROS. Endogenous antioxidant capacity was not depleted, and the MDA-MB-231 cells were 
protected from any adverse effects.  
Literature has shown conflicting results regarding this topic, and some studies have observed 
anti-proliferative effects of CBD on MDA-MB-231 (Ligriesti et al., 2006; McAllister et al., 2011), 
where other studies have reported no effect of CBD exposure (Velasco et al., 2012), as 
experienced in this study, and some have reported pro-tumorigenic effects of CBD exposure 
(Zhu et al., 2000).  
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Despite the large body of literature that currently exists regarding Cannabis sativa and its 
Phytocannabinoids such as cannabidiol and Δ9-THC in the context of medicine and disease 
treatment, very little exists in the context of oxidative stress mediated cancer therapy and 
the antioxidant capacity of CBD in this context. This alone illustrates the importance of 
research in this area, and the contribution of this study to this topic. Overall, exposure to 
cannabidiol may be a favourable treatment for breast cancers that are estrogen receptor 
positive, as the MCF7 cell line showed the greatest cytotoxicity and adverse effects when 
exposed to this extract across all doses assessed. The MCF12A cell line experienced fewer 
adverse effects than the MCF7 model and were able to better tolerate the cannabidiol extract. 
However, MDA-MB-231 cells also experienced an increased survival upon exposure to CBD, 
with no toxic effects. Thus, cannabidiol should not be used as a treatment for estrogen 
receptor negative cancers, indicating the importance in considering the stage and estrogen 
status of the breast cancer prior to treatment. This warrants further research in this context, 
however a maximum dose needs to be determined in the context of breast cancer, because 
predictable dose response was lost at a certain threshold in the MCF12A and MDA-MB-231 
cell lines. Finally, it is also important to note that studies in vitro may not always translate 
directly in vivo, but results obtained in this study regarding Cannabidiol are promising. 
 
5.3 Insights on drug interactions 
Very little literature exists in the context of combination therapies using CBD in the treatment 
of cancer or specifically, breast cancer. In order to gain a better understanding of this, 
literature from other niches had to be considered and studied. One study assessed the 
cardioprotective effects of Cannabidiol when taken in combination with doxorubicin in cancer 
(Fouad et al., 2013). Cannabidiol, when taken in combination with doxorubicin reduced the 
expression of TNF levels associated with doxorubicin exposure, in addition to reduced NO 
levels, cardiac malondialdehyde expression and troponin-T levels. This resulted in a 
cardioprotective effect, reducing the cardiotoxicity associated with doxorubicin exposure, in 
part of which was mediated by decrease inflammation and oxidative stress, which is in line 
with the scope of this study. In addition to this, there is a large body of work that examines 
the neuroprotective effect of CBD. One such study examined the protective effect of 
Cannabidiol in the context of neurotoxicity, in which retinal ganglion cells were exposed to N-
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methyl-D-aspartate (NMDA), resulting in increased peroxynitrite accumulation and cell death 
(El-Remessy et al., 2003). Cells which were exposed to NMDA and CBD in combination had 
reduced neurotoxicity as a result of decreased peroxynitrite production, and suggests 
Cannabidiol may have a potential use in Glaucoma treatment. This further demonstrates the 
potential protective effect of Cannabidiol. 
Using information gained from previous studies, the drug interactions between Δ-7 
mesembrenone and Cannabidiol were considered. Combinations with high dose Δ-7 
mesembrenone (2 and 3) resulted in significant decreases in cell viability and mitochondrial 
reductive capacity in the MCF12A that were not countered by exposure to high doses of 
Cannabidiol. In addition to this, all combinations resulted in increased ROS production similar 
to that generated by Δ-7 mesembrenone in isolation, further indicating that CBD was not 
potent enough to counter these negative effects, even at high doses. In this case, combination 
exposure was even more detrimental to MCF12A cells and the highest Δ-7 mesembrenone 
and CBD combination resulted in total depletion of endogenous glutathione activity. 
Combinations of both antioxidants may have resulted in an antioxidant overload, resulting in 
an increased production of free radicals that could not be scavenged entirely.  
MCF7 cells had similar results upon exposure to the combination doses as the MCF12A cell 
model in terms of cell viability and mitochondrial reductive capacity and increased ROS 
production. As previously mentioned, this may be as a result of a variety of factors. Firstly, he 
estrogen receptor status of this cell line and its increased sensitivity to ROS may be a 
contributing factor. Secondly, the fact that certain tumour cells metabolise CBD specifically 
via a pathway promoting ROS generation, as well as a potential antioxidant overload in these 
cells, shifting towards a pro-oxidative state. In addition to this, as previously mentioned, MCF7 
cells have a particular sensitivity to CBD exposure, resulting in cell cycle arrest and inhibition 
of proliferation (Caffarel et al., 2012). Finally, endogenous glutathione was depleted almost 
entirely when the extracts were used in their highest combinations, which correlates with the 
increased ROS production observed. 
Results for MDA-MB-231 cells were not so severe, but again indicate that CBD was unable to 
remove the negative effects associated with Δ-7 mesembrenone exposure. Significant 
changes in ROS production was only observed in combination 3, which may be due to an 
antioxidant over load considering the high doses of Δ-7 mesembrenone and CBD used in this 
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combination. This increase in ROS production correlates with the decrease in cell viability. No 
changes were observed in the ratio between GSH and GSSG across any of the combinations 
assessed, which may indicate that the cells are able to tolerate higher levels of ROS as 
previously discussed. 
While Cannabidiol has been able to counter toxicity induced by other chemicals or drugs in 
previous studies, it was unable to counter the negative effects associated with Δ-7 
mesembrenone exposure. This may be due to the fact that CBD was not potent enough to 
protect the cells from Δ-7 mesembrenone exposure, and the beneficial effects of CBD in 
isolation were totally lost when used in these combinations. In some cases, at the highest 
doses of CBD and Δ-7 mesembrenone, a cumulative effect was observed, further perpetuating 
oxidative stress and antioxidant depletion. This indicates that not enough information is 
known about each extract to validate their compound use, and this is in line with a previous 
paper by Casedas and co-workers, in which it states that certain extracts do not have enough 
information about them to validate their responsible compounding (Casedas, et al., 2018). 
Not enough is understood about the conditions under which seemingly beneficial 
supplements may become detrimental. 
 
5.4 Concluding remarks 
In the context of cancer therapy or prevention, Δ-7 mesembrenone isolated from Sceletium 
tortuosum was not effective. Exposure to Δ-7 mesembrenone resulted in detrimental effects 
to the normal breast cell line which outweighed any potential anti-cancer benefits observed 
in both the breast cancer cell models. However, further research may be conducted in the 
context of Δ-7 mesembrenone at lower doses as a potential antioxidant supplement. 
Cannabidiol showed more promise in this context, where healthy breast cells showed less 
adverse effects upon exposure to CBD, with the estrogen receptor positive breast cancer 
exhibiting more detrimental effects. This is a beneficial outcome, whereby normal breast 
tissue remains healthy upon exposure to CBD, where the MCF7 breast cancer did not. Further 
research could be done in order to better understand the effect of Cannabidiol treatment in 
estrogen receptor positive breast cancer therapy. However, this treatment had no anti-cancer 
activity when the estrogen receptor negative breast cell line was exposed to increasing doses 
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of Cannabidiol. Finally, in terms of a combination therapy, the Cannabidiol was unable to 
counter the harsh side effects of Δ-7 mesembrenone exposure. Therefore, the combination 
treatments would have little benefit in the context of breast cancer therapy. 
 
5.5 Future research 
Future research should be conducted to further investigate the anti-cancer potential of 
Cannabidiol in the treatment and prevention of estrogen receptor positive breast cancers. In 
addition to this, the dose at which the Cannabidiol shows detrimental effects within the 
normal breast tissue should also be elucidated and better understood. Investigations may also 
be conducted in vivo in order to determine whether the results obtained in the in vitro 
experiments translate to animal models, which is not always the case. 
Furthermore, investigations should be conducted into the redox status of each breast cancer 
cell type, as well as any other cell type exposed to these two extracts, in order to better 
understand the cellular mechanisms at play. Each cell type has its own inherent oxidative 
stress basal level, as well as their own endogenous antioxidant mechanisms and capacities. 
This would need to be studied prior to further treatment in order to elucidate whether the 
relevant treatment would be effective or not. 
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